

47th ANNUAL REPORT 2009/2010



EMS Group

2
4
5
8
9

Financial Statements

EMS Group	Consolidated Income Statement	19
Consolidated data	Consolidated Balance Sheet	20
for the calendar year 2009	Consolidated Statement of Changes in Equity	21
	Consolidated Statement of Cash Flows	22
	Notes to the Consolidated Financial Statements	23
	Report of the Statutory Auditor on the Consolidated Financial Statements	58
EMS-CHEMIE HOLDING AG	Income Statement	60
data for the financial year	Balance Sheet	61
May 1, 2009 – April 30, 2010	Notes to the Financial Statements	62
	Proposal of the Board of Directors for the appropriation of available earnings	67
_	Report of the Statutory Auditor on the Financial Statements	68
	Addresses of EMS Companies, Switzerland	69
	Addresses of EMS Companies, Worldwide	70

Dear Shareholden

2009 will remain long in our memories as a year of extremes: after a very sharp downturn in the economy in the fourth quarter of 2008, the business environment declined even further at the beginning of 2009. The automotive industry, which is of key importance to EMS, collapsed by almost half. All over the world, small and large companies alike were fighting for survival. Numerous businesses had to lay off large proportions of their workforces, or even shut down. Governments promised comprehensive aid and launched economic stimulus packages. Panic spread far and wide.

Several of EMS' customers closed their production altogether until well into January 2009. Customers were hugely uncertain about the future, and this also had an impact on EMS: order volumes fell and reduced working hours became necessary for many EMS employees in production and logistics. However, others voluntarily worked overtime to boost new business in the market. It was especially during these difficult times that our customers appreciated EMS' close contact and technical support, and several doors were opened to innovative new business collaborations.

Thankfully, EMS was well prepared for an economic downturn. Already in the previous year expecting a weaker economic situation, the company launched cost-cutting programmes and scaled back investments, before introducing a worldwide recruitment freeze in April 2008. It is thanks to these measures, taken unusually early, that EMS did not have to make significant headcount reductions and was able to resolutely continue its business throughout the crisis. EMS continued to pursue its goals undeterred and consistently implemented its strategy for the expansion of its speciality business in the core area of Performance Polymers. The voluntary overtime worked by all employees worldwide in the areas of research, development, marketing and sales was aimed at successfully achieving more new applications at a faster rate. Meanwhile, EMS invested in the growth markets China, India and Brazil during the crisis, setting up new production sites.

The second half of 2009 proved to be just as unusual as the first – the results were extraordinarily good, and sales recovered significantly. With confidence in the future increasing, customers began to replenish their – earlier greatly reduced – inventories, and order volumes at EMS soared. This allowed the company to abandon reduced working hours and even to hire staff again. New business additionally improved the order situation.

Overall, net sales for 2009 totalled CHF 1 198 million, clearly below the previous year's figure. However, the operating result (EBIT) of CHF 222 million was slightly higher than the equivalent figure in 2008. The 2009 EBIT margin even climbed to an all-time high of 18.5 %!

Crises force changes and improvements, and also provide opportunities. The takeover in November 2009 of the specialist fibre manufacturer Nexis Fibers based in Neumünster, Germany, was one such opportunity for EMS. The takeover enabled EMS to strongly expand its own global business in specialties technical fibres.



For 2010 EMS anticipates sustained recovery of the global economy. The focus is now on realising the initiated new business and generating more for the future. There are sure to be some challenges along the way. The rapidly increasing cost of raw materials as well as unfavourable currency conditions will have a negatively influence on results. The new growth markets on the other hand will continue to develop very strongly – particularly China. With its new production sites in China, India and Brazil, EMS is well prepared to meet this new and increasing demand.

The burden on employees and managers is especially high in times of crisis. The EMS staff showed commitment, willingness and loyalty during the extremely difficult year 2009. Our sincere thanks to all concerned. This makes us confident that we can successfully overcome the challenges ahead together and achieve good performance and results again in the coming years.

We would like to take this opportunity to thank you as shareholders for the trust you have placed in EMS even in these difficult times and for your valued loyalty to our company. We look forward to continuing our journey with you.

My Ay. M. Martullo

Dr Ulf Berg Chairman of the Board of Directors

Magdalena Martullo

Vice-Chairman of the Board of Directors and Chief Executive Officer

	2009	2008	2007	2006	2005
Number of registered shares	23 389 028	23 389 028 ¹⁾	25 052 870	25 052 870	25 052 870
Number of	20007020	20007020	23032070	23 032 07 0	23 032 070
Shares entitled to dividend	22 373 911	22373911	24 025 654	22718364	23810571
Treasury shares	1015117	1015117	1027216	2 334 506	1 242 299
Information per share (in CHF):					
Dividend per share	10.00 2)	5.00	7.25	8.00	6.50
Of which ordinary dividend	5.00	5.00	6.00	5.50	5.00
Of which special dividend	5.00	-	1.25	2.50	1.50
Earnings per share	9.66	9.25	12.14	12.99	7.30
Cash flow per share 3)	12.47	11.95	15.22	15.67	9.85
Equity per share 4)	45.67	42.61	54.71	48.15	44.64
Stock prices ⁵⁾					
High	125.00	165.22	170.00	147.00	116.90
Low	80.00	82.25	144.06	117.00	93.43
At December 31	123.80	88.50	166.60	146.60	116.50
Market capitalisation on December 31 (CHF millions)	2895.6	2069.9	4173.8	3672.8	2918.7

Registered shares are listed on the SIX Swiss Exchange.

Security number ISIN Investdata/Reuters EMS-CHEMIE 1.644.035 CH0016440353 EMSN

As part of a share buyback, 1 663 842 registered shares were canceled on November 3, 2008.
 Proposal of the Board of Directors.
 Cash flow = net income plus write-downs on intangible assets, property, plant and equipment plus value adjustments to securities.
 Inclusive non-controlling interests.

⁵⁾ Source: Bloomberg

Business performance

The 2009 financial year was one of two entirely distinct halves. The first six months were characterised by very weak demand due to the economic situation, while the second half saw a clear recovery. Net sales for the 2009 financial year as a whole nevertheless remained well below the figure for the previous year. Despite the crisis, EMS successfully achieved its growth targets for new business in the core Performance Polymers business. There was an encouraging performance in new metal replacement applications while automotive supplier EMS-EFTEC continued to gain market share worldwide.

The volumes produced by customers unfortunately showed a decline due to the economic situation, above all in the first half of the year, and this also had an impact on volume demand at EMS. EMS adapted itself to the economic decline at a very early stage, launching extensive cost-cutting programmes already in 2008 accompanied by a worldwide recruitment freeze and reduction in current assets. Reduced costs and profitable new business – despite lower net sales – actually resulted in a higher net operating income (EBIT) compared with the previous year, as well as an exceptionally high EBIT margin.

Net sales in Swiss francs reached CHF 1 198 million (1 504), and were therefore 20.4 % lower than in the previous year. On a local-currency basis, the reduction versus the previous year came to 17.6 %. At CHF 222 million (220), net operating income (EBIT) was 1.0 % higher than in the previous year; this was due to a very profitable second half. The EBIT margin grew from 14.6 % to 18.5 %. EBITDA totalled CHF 280 million (278). Net financial income amounted to CHF 28 million (38). Net income after taxes stood at CHF 221 million (215) and was therefore also above the previous year's level.

EMS has an innovative, high-margin specialty business. It will continue to pursue its successful strategy for expanding its specialty business in the core area of Performance Polymers. Worldwide market positions are continuing to be expanded. In the new growth markets of China, India and Brazil, this is occurring also via newly established sales and production sites.


For 2010, EMS expects a continuing recovery in worldwide economic activity. Demand is also being fuelled by low inventory levels, especially in the automotive industry. The new growth markets – led by China – will continue to develop in a highly positive manner. With its newly commissioned production sites, EMS is well equipped to deal with the additional demand in these countries. Further capacity expansions, including at the Domat/Ems site in Switzerland, are already at the implementation stage and will in some cases start operation in 2010. On the commodity markets, higher demand is causing shortages and rising prices. To secure its own margins, EMS therefore needs to pass price increases on to its customers.

Overall, EMS is optimistic about business prospects in 2010. Net sales as well as net operating income (EBIT) are likely to exceed the previous year's figures.


Investments

In light of the economic downturn, EMS had planned a low level of investment in 2009. Capacity was expanded mainly in Asia and Brazil. Overall investment in 2009 came to CHF 38 million (64). As in previous years, investments were financed from internal resources thanks to a high cash flow of CHF 279 million (273). One of EMS' strengths is the fact that it always generates a strong free cash flow – both in good and in challenging years.

Investment by application



Investment by country and region



Management structure

At the 2009 Annual General Meeting, Magdalena Martullo, Dr Hansjörg Frei, Dr Werner Prätorius and Dr Ulf Berg were elected to the Board of Directors for a further one-year term of office. Owing to other commitments, Egbert Appel decided not to put himself forward for a further term of office.

Personnel

At the end of December 2009, the EMS Group had a total of 2106 (2165) employees (excluding apprentices), of whom 984 (1057) work in Switzerland, 676 (601) in the rest of Europe, 275 (280) in Asia and 171 (227) in America. At the end of the year, the EMS Group employed 137 (129) apprentices in Switzerland covering 15 (14) different vocational fields. A total of 29 (33) apprentices successfully completed their professional training during the year under review.

Breakdown of EMS Group net sales by country / region

, , , ,	
Germany	28.0%
USA	9.8%
China	9.0%
France	8.3%
Japan	6.8%
Italy	5.3%
Switzerland	4.7%
Spain	3.3%
Great Britain	2.8%
Austria	1.8%
South Korea	1.7%
Taiwan	1.7%
Czech Republic	1.6%
Sweden	1.5%
Netherlands	1.3%
Mexico	1.1%
Rest of Europe	6.2%
Others	5.1%

Breakdown of EMS Group production by country / region

Switzerland	53.4%
Germany	12.0%
USA	8.3%
Belgium	7.6%
China	4.4%
Japan	4.2%
Great Britain	2.8%
Taiwan	2.7%
Czech Republic	2.3%
Others	2.3%

Research and development

Expenditure on research and development in the financial year amounted to 3.3 % (3.2 %) of net sales (see Note 4 to the Financial Statements).

Business areas

The EMS Group operates globally in the business areas of Performance Polymers and Fine Chemicals / Engineering. These areas are further broken down into Business Units.

Performance Polymers

EMS-GRIVORY consists of three independent, profitresponsible Business Units and produces customised high-grade polymer materials (as polyamide granules). Thanks to their high-performance properties and ability to cut processing costs, these materials are used in a variety of applications, particularly in the automotive, in the electrical and electronics industry, in optics, as well as in numerous other industrial sectors. EMS-GRIVORY Europe specialises in innovative solutions for customers in the field of injection moulding as well as extrusion and extrusion blowmoulding applications in Europe. EMS-GRIVORY Asia operates in the Asian market. EMS-GRIVORY America is responsible for business in North America.

The EMS-EFTEC Business Unit is a specialist supplier to the global automotive industry in the areas of bonding, coating, sealing and damping.

Since January 1, 2009, the EMS-GRILTECH Business Unit has been managed within the Fine Chemicals / Engineering business area.

In 2009, the core business area of Performance Polymers generated net sales of CHF 986 million (1 241) and net operating income (EBIT) of CHF 192 million (192). The poor economic situation, particularly in the first half of 2009, hugely impaired the volume trend for existing business. Nonetheless, the company further expanded its worldwide market position and successfully achieved new business targets.

Fine Chemicals / Engineering

The EMS-PRIMID Business Unit was integrated into the EMS-GRILTECH Business Unit on May 1, 2009 in order to improve the results situation and market presence. EMS-GRILTECH specialises in the development and production of fibres, hotmelt adhesives and fusible bonding yarns for technical and textile applications, bonding agents for high-performance tyres, powder coating crosslinkers and reactive diluents.

The EMS-PATVAG Business Unit produces ignitors for airbag gas generators.

The Fine Chemicals / Engineering business area generated net sales of CHF 212 million (263) and net operating income of CHF 30 million (28) in 2009.

CHF millions	2009	2008	2007	2006	2005	
Net sales revenue	1 197.7	1 503.9	1 552.4	1 395.9	1 253.3	
Change in % against previous year	-20.4%	-3.1%	+11.2%	+11.4%	+9.1%	
Change in local currencies	-17.6%	+0.8%	+9.2%	+10.3%	+8.4%	
Of which in Switzerland	4.7%	5.1%	5.0%	4.8%	4.4%	
Net operating income (EBIT)	221.8	219.6	270.2	246.8	216.4	
Change in % against previous year	+1.0%	-18.7%	+9.5%	+14.1%	+6.4%	
In % of net sales revenue	18.5%	14.6%	17.4%	17.7%	17.3%	
Net financial income	27.9	37.5	63.7	118.3	10.9	
Change in % against previous year	-25.5%	-41.1%	-46.1%	+981.2%	-40.2%	
Income taxes	28.5	41.9	40.1	57.4	45.5	
Net income	221.2	215.2	293.8	307.7	181.9	
Change in % against previous year	+2.8%	-26.7%	-4.5%	+69.2%	+0.8%	
In % of net sales revenue	18.5%	14.3%	18.9%	22.0%	14.5%	
Cash flow 1)	279.0	273.4	355.3	358.8	239.0	
Change in % against previous year	+2.1%	-23.0%	-1.0%	+50.1%	-3.2%	
In % of net sales revenue	23.3%	18.2%	22.9%	25.7%	19.1%	
Investments	37.6	63.7	71.9	64.3	48.8	
In % of cash flow	13.5%	23.3%	20.2%	17.9%	20.4%	
Balance sheet total	1711.3	1 679.4	2 277.1	2 328.6	2350.4	
Assets						
Current assets	1141.9	1 083.6	1671.8	1 733.0	1816.9	
Non-current assets	569.4	595.9	605.3	595.6	533.5	
Equity and liabilities						
Current liabilities	417.0	221.2	614.2	339.0	315.0	
Non-current liabilities	272.5	482.9	386.2	886.8	952.6	
Equity ²⁾	1021.7	975.3	1 276.7	1 102.7	1 082.9	
Balance sheet equity ratio	59.7%	58.1%	56.1%	47.4%	46.1%	
Return on equity	21.7%	22.1%	23.0%	27.9%	16.8%	
Number of employees on December 31 ³⁾	2106	2165	2231	2061	2055	

¹⁾ Cash flow = net income plus write-downs on intangible assets, property, plant and equipment plus value adjustments to securities.
 ²⁾ Inclusive non-controlling interests.
 ³⁾ Excluding apprentices (2009: 137; 2008: 129; 2007: 109; 2006: 112; 2005: 119).

Corporate Governance

EMS-CHEMIE HOLDING AG, a holding company by Swiss law, is committed to responsible corporate governance and oversight. The structure and content of this report comply with the SIX Swiss Exchange Directive on Information Relating to Corporate Governance (DCG). Detailed principles and rules are also laid down in the company's Articles of Association at www.ems-group.com/annualreport/2010/ articlesofassociation and in the Organisational Rules of the EMS Group at www.ems-group.com/annualreport/2010/organisationalrules. All data refer to the situation as at December 31, 2009, except where stated otherwise.


1. Group structure and shareholders

1.1 Group structure

The EMS Group is active worldwide in the two business areas Performance Polymers and Fine Chemicals/ Engineering. The organisational breakdown is based on product types. The Group's operating structure is as follows: The companies of the EMS Group are grouped together in the EMS-CHEMIE HOLDING AG, which has its registered office in Domat/Ems, Switzerland. EMS-CHEMIE HOLDING AG is the only listed company within the scope of consolidation. EMS registered shares (EMSN, ISIN: CH0016440353) are listed on the SIX Swiss Exchange. As at December 31, 2009, the market capitalisation of EMS amounted to CHF 2895.6 million. None of its subsidiaries hold any EMS registered shares.

An overview of the unlisted subsidiaries belonging to the consolidated EMS Group can be found in note 30 in the financial section.

Segment reporting by business area and geographical region can be found on page 31.



EMS Group Corporate Governance Annual Report 2009/2010

1.2 Significant shareholders

In the calendar year 2009, three shareholders each held more than 3% of the equity of EMS-CHEMIE HOLDING AG:

During the whole calendar year EMESTA HOLDING AG, held 51.70%, Miriam Blocher 8.89% and EMS-CHEMIE HOLDING AG 4.34% (treasury shares).

As at February 15, 2010, EMS-CHEMIE HOLDING AG sold its treasury shares (4.34%) to EMESTA HOLDING AG. EMESTA HOLDING AG holds consequently 56.04% of the capital shares of EMS-CHEMIE HOLDING AG.

1.3 Cross-shareholdings

There are no cross-shareholdings with other companies.

2. Capital structure

2.1 Capital/

2.2 Authorised and conditional capital in particular

The ordinary share capital of EMS-CHEMIE HOLDING AG amounts to CHF 233890.28. No authorised or conditional capital exists.

2.3 Changes in capital

Information on capital changes can be found on page 4 (Spotlight on Share Performance), in the financial section on page 21 (Consolidated Statement of Changes in Equity) and in note 14 (Share capital).

2.4 Shares and participation certificates /2.5 Profit sharing certificates

The fully paid share capital is divided into 23389028 registered shares with a par value of CHF 0.01 each. All registered shares are entitled to dividends. Each registered share entitles the holder to one vote at the Annual General Meeting. No participation certificates or profit sharing certificates exist.

2.6 Limitations on transferability and nominee registrations

On request, purchasers of shares of EMS-CHEMIE HOLDING AG are entered in the share register as voting shareholders without restrictions, provided they expressly declare that the registered shares were acquired in their own name and on their own account.

The Board of Directors may enter people whose request for registration does not include an express declaration that they hold the shares on their own account ("Nominees"), and with whom the company has entered into an agreement to this effect, in the register of shareholders with voting rights up to a maximum of 2% of the share capital entered in the commercial register.

The Articles of Association do not provide for any privileges or restrictions on transferability.

2.7 Convertible bonds and warrants / options

Details of the outstanding convertible bond are set out in note 17. No warrants / options have been issued.

3. Board of Directors

3.1 Members of the Board of Directors /

3.2 Other activities and vested interests

Board of Directors

Name	Nationality	Status	Year of birth	First elected in	Term of office expires
Dr Ulf Berg	Swiss	Non-executive	1950	August 2007	2010
Magdalena Martullo	Swiss	Executive	1969	August 2002	2010
Dr Hansjörg Frei	Swiss	Non-executive	1941	January 2003	2010
Dr Werner Prätorius	German	Non-executive	1946	September 2006	2010

On December 31, 2009, the Board of Directors of EMS-CHEMIE HOLDING AG consisted of the following four members:

Dr Ulf Berg Iborn in 1950, Swiss citizen, graduate engineer with a PhD in mechanical engineering) has been non-executive Chairman of the Board of Directors since August 2007. He worked for ABB (formerly BBC) in various managerial positions in Switzerland and abroad for more than 20 years until 1998. Between 1999 and 2001 he was COO and CEO of Carlo Gavazzi Holding AG. From 2003 to 2004 he was CEO of SIG Beverages Int. AG, before moving to Sulzer AG, Switzerland in 2004 as CEO, a position he held until 2007. From 2007 to 2009 Dr Berg has been a non-executive Chairman of the Board of Directors of Sulzer AG, Switzerland. Since 2004 Dr Berg has been a member of the Board of Directors of Swissmem, Switzerland and since 2006 a member of the Board of Directors of Bobst SA, Switzerland. From 2004 to 2009 Dr Berg has been a member of the Board of Directors of Venture Incubator AG, Switzerland and from 2007 to 2009 a member of the Board of Trustees of Avenir Suisse. Since 2008 he has been member of the Supervisory Board of the SAG GmbH in Langen, Germany and since 2009 non-executive Chairman of the Board of Directors of Midland Cogeneration Venture LLP in Midland, Michigan, USA. Dr Ulf Berg is owner of the EG Energy Group Ltd. in Zug, Switzerland and partner at BLR & Partners Ltd. in Thalwil / Zurich.

Magdalena Martullo (born in 1969, Swiss citizen, Master of Business Administration) has been executive Vice-Chairman of the Board of Directors since August 2002 and CEO since January 2004. She joined the EMS Group in January 2001 and became a member of the Board of Directors in August 2001. As CEO, Magdalena Martullo bears overall operating responsibility for the EMS Group. After performing various functions both in Switzerland and abroad, Magdalena Martullo was a Product Manager at Johnson & Johnson AG from 1994 to 1996. She then went on to work at Rivella AG until 2000, where her last position was Head of Marketing for Switzerland and member of the company's extended Senior Management. Since June 2004, Magdalena Martullo has been a member of the Executive Board of SGCI Chemie Pharma Schweiz, where she leads the Board Committee on economic policy.

Dr Hansjörg Frei (born in 1941, Swiss citizen, Doctor of Law) has been a non-executive member of the Board of Directors and Chairman of the Pension Fund of the EMS Group since January 2003. For many years Dr Frei held various management positions in the insurance industry. At the Winterthur insurance company, his last position until 2000 was as a member of the Group Executive Board in charge of Swiss operations. Following the company's merger with Credit Suisse, he was a Member of the Executive Board (Head of International Country Management) of Credit Suisse Financial Services until 2003. From 2000 to 2003, he was Chairman of the Swiss Insurance Association (SVV). Dr Hansjörg Frei has been a non-executive member of the Board of Directors of Bâloise-Holding since 2004.

Dr Werner Prätorius (born in 1946, German citizen, Doctor of Chemical Engineering) has been a nonexecutive member of the Board of Directors since September 2006. He spent almost 30 years with BASF, where he was responsible for a wide variety of national and international tasks. From 1995 to 2006 he was successively Head of the Engineering Plastics, Styrenic Polymers and Petrochemicals Divisions. Dr Prätorius has also been a member of the most important European trade organisations for chemicals and plastics such as the Association of Plastics Manufacturers in Europe (1994–2004), the Association of European Petrochemicals Producers (2002–2006) and the European Petrochemical Association (2001–2006).

None of the non-executive members of the Board of Directors have ever been a member of any Senior Management within the EMS Group. None currently have a direct or indirect business relationship with companies in the EMS Group.

3.3 Elections and terms of office

Each member of the Board of Directors is elected individually by the Annual General Meeting for a one-year term of office. There is no limit on the total term of office; members may be re-elected.

Attendance at meetings of the Board of Directors and committees

Name	Function	Atte	Attendance at meetings				
		Board of Directors	Audit Committee	Compensation Committee			
Dr Ulf Berg	Chairman	91)	6	3			
Magdalena Martullo	Vice-Chairman and CEO	9					
Dr Hansjörg Frei	Member	9	61)	311			
			(Chairma	an from August 9, 2009 on)			
Dr Werner Prätorius	Member	8		1			
				(since August 9, 2009)			
Egbert Appel	Member	5		21)			
		luntil August 8, 2009)		(until August 8, 2009)			
Total meetings		9	6	3			
Total duration (hours)		2 – 7	1 – 3	2 - 3			

¹¹ Chairman

3.4 Internal organisational structure

Duties of the Board of Directors

The Board of Directors is the highest executive body of the EMS Group. It is responsible for supervising and monitoring the company's management and that of its affiliated companies which together form the EMS Group. Every year at its constituent meeting, the Board of Directors elects a Chairman and a Vice-Chairman from among its members. The Board of Directors has delegated most of the operational management of the EMS Group to the CEO. Special tasks can be delegated to individual members of the Board of Directors or to separate special committees.

Board committees: Members, tasks, areas of responsibility

There are two committees: the Audit Committee and the Compensation Committee. Their tasks and responsibilities are set out in guidelines (www.emsgroup.com/annualreport/2010/organisationalrules). Both committees have assessment, advisory and monitoring functions but no decision-making powers.

The Audit Committee consists of two non-executive, independent members of the Board of Directors: Dr Hansjörg Frei, Chairman, and Dr Ulf Berg, member. It assesses the effectiveness of external reporting, internal finance and accounting, internal control systems and compliance with accounting principles. The Audit Committee makes recommendations to the entire Board of Directors regarding presentation of individual and consolidated financial statements to the Annual General Meeting. It also assesses the performance and remuneration of the external auditors.

The Compensation Committee consists of three non-executive members of the Board of Directors: E. Appel, Chairman until August 8, 2009, Dr Hans jörg Frei, Chairman since August 9, 2009, Dr Ulf Berg, member, Dr Werner Prätorius, member since August 9, 2009. The Compensation Committee is concerned with the remuneration policy of the EMS Group (Board of Directors, Senior Management, senior executives).

Working methods of the Board of Directors and its committees

The Board of Directors and its committees meet as frequently as business demands and at least six times

a year. The Board of Directors held nine meetings in 2009, each lasting between two and seven hours. The Audit Committee held six meetings, each lasting between one and three hours, while the Compensation Committee held three meetings, each lasting between two and three hours.

The Head of Finance (CFO) also attends the meetings of the Board of Directors. Other members of Senior Management and Heads of Business Units are invited to attend meetings of the Board of Directors when it discusses matters relevant to their areas of responsibility. To constitute a quorum, a majority of the members of the Board of Directors must be present. The Board of Directors makes decisions and carries out elections with a majority of the members present at the meeting. In the event of a tie, the Chairman has the casting vote. Resolutions can also be passed by way of telephone conferences or by circular, provided that no member requests discussion in person. Resolutions passed in this way must be unanimous to be valid. Individual members are obliged to abstain from voting on personal matters or on matters involving persons with whom they are closely associated.

Members of Senior Management are invited to attend committee meetings where matters relevant to their areas of responsibility are to be discussed. The provisions relating to meetings and resolutions of the Board of Directors and to the requirement for its members to abstain, also apply to the committees. At the next plenary meeting of the Board of Directors after their committees have met, the committee Chairmen report on the proceedings and submit proposals to the Board for its decision. Further details of internal organisation can be found in the Organisational Rules of the EMS Group at www.ems-group.com/annualreport/2010/ organisationalrules.

3.5 Definition of areas of responsibility

The Board of Directors makes decisions regarding all matters not reserved for the Annual General Meeting or another body by law, the Articles of Association or the Organisational Rules. Subject to article 716 a of the Swiss Code of Obligations (nontransferable and inalienable duties of the Board of Directors), the Board of Directors has delegated most of the operational management of the EMS Group to Senior Management. These duties and responsibilities particularly include proposing

the strategy for the EMS Group to the Board of Directors, achieving the operative and financial results of the EMS Group, reviewing the budgets and medium-term plans of Business Units, deciding on scheduled capital investments up to CHF 5 million and on unscheduled capital investments up to CHF 0.5 million, reaching decisions on the procurement of external capital (e.g. bonds, bank loans) up to CHF 30 million, issuing guarantees in accordance with the guarantee concept proposed to the Board of Directors, receiving periodic reports on business performance and all other significant events, deciding on the initiation and conduct of legal proceedings and submitting proposals to the Board of Directors for legal proceedings of fundamental significance, approving the organisation up to the level of employees directly subordinate to Heads of Business Units, submitting proposals to the Board of Directors on the acquisition and disposal of equity holdings, assigning powers to the members of the board of trustees who protect the interests of the employer in EMS Group pension schemes, proposing authorised signatories to the Board of Directors, permitting heads of Business Units and their direct subordinates to accept seats on Boards of Directors, political offices or honorary offices, enacting the rules of the EMS Group and maintaining personal contact with senior managers of other companies and with important customers.

3.6 Information and control instruments vis-à-vis the Senior Management

At the end of each month the Board of Directors receives a written report from the CEO regarding business performance during that month and the expected monthly result. On the 4th working day of the following month, it receives the monthly income statement with the most important key figures, which are compared with the budgeted figures and those of the previous year. It is also provided, in the same detail, with monthly updated forecast calculations for the end of the year. This serves to monitor the achievability of the budget. If actual monthly results deviate from the budget by more than 10%, the CEO submits a report to the Board of Directors by the middle of the following month analysing the deviation in result and detailing corrective measures, both planned and already implemented. In addition, the Board of Directors receives consolidated guarterly financial statements prepared in accordance with IFRS. Along with the income statement, these mainly provide information on the balance sheet, the cash flow account and changes in equity. Furthermore, at each meeting of the Board of Directors, the CEO and CFO report on the course of business and on all matters relevant to the Group, while the two committee Chairmen report on the matters they have dealt with, detailing their significant findings and assessment and submitting proposals accordingly. Every year, the Board of Directors discusses and approves the budget for the following year, as well as rolling medium-term planning for the next three years. The CEO informs the members of the Board of Directors of any extraordinary events without delay by circular or other appropriate means. At Board meetings, any member of the Board may request information from other members or from Senior Management on any of the company's affairs. Between meetings of the Board of Directors, any member may request information from the CEO on the course of business, and – with the approval of the Chairman – on specific business events, and/or may inspect business documents. At their own discretion, members of the Board of Directors visit Group companies and participate in the twomonthly Management Meetings held by Senior Management with the Heads of the Business Units in order to form an independent view of the Group's operating activities and the implementation of its strategy.

During the year under review, 25 audits were conducted by Group Financial Controlling at Group companies, mainly focusing on accounting and compliance. Group Financial Controlling discusses all audit findings in detail with the companies and Business Units concerned, and the most important measures are agreed on. In the event of disagreement between the auditors and the company audited, the different positions are stated transparently. An audit report is prepared containing the overall audit findings. Members of the Audit Committee, the CEO and the CFO each receive a copy of every audit report. Following each audit report, the CEO and CFO present the Audit Committee with the measures to be implemented by Group management. All significant measures are continuously monitored by the Audit Committee. In the event of discrepancies, the CEO and CFO must comment on them and present proposals for corrective measures. Although Group Financial Controlling is subordinate to the CFO, it reports directly to the Chairman of the Audit Committee with regard to these activities. Group Financial Controlling also regularly keeps the Audit Committee informed of

such changes in the field of accounting. The legal service of the EMS Group reports regularly to the Board of Directors on any legal changes important to EMS. Twice a year, the Audit Committee is notified of all litigation cases that are underway or impending. Besides the status of the individual cases, the report focuses on risks and opportunities they represent, costs and other possible effects.

Risk management constitutes an integral component of planning and reporting activities at EMS. At Senior Management and Business Unit level, risks are identified annually as part of the medium-term planning procedure and preparation of the budget for the following year. They are then weighted according to the gravity of the risk and probability of its occurrence. The identification and assessment of changes in risk play an important part in this process. Measures are defined to reduce significant risks. In the course of planning discussions, the CEO and CFO report to the Board of Directors on the magnitude of these risks and the implementation status of the measures taken to counter them.

4. Senior Management

4.1 Members of Senior Management /4.2 Other activities and vested interests

On December 31, 2009, Senior Management of EMS-CHEMIE HOLDING AG consisted of the following three persons:

Magdalena Martullo (born in 1969, Swiss citizen, Master of Business Administration) has been executive Vice-Chairman of the Board of Directors since August 2002 and CEO since January 2004. She joined the EMS Group in January 2001 and became a member of the Board of Directors in August 2001. As CEO, Magdalena Martullo bears overall operating responsibility for the EMS Group. After performing various functions both in Switzerland and abroad, Magdalena Martullo was a Product Manager at Johnson & Johnson AG from 1994 to 1996. She then went on to work at Rivella AG until 2000, where her last position was Head of Marketing for Switzerland and member of the company's extended Senior Management. Since June 2004, Magdalena Martullo has been a member of the Executive Board of SGCI Chemie Pharma Schweiz, where she leads the Board committee on economic policy.

Peter Germann (born in 1959, Swiss citizen, Master of Business Administration) has been the EMS Group's Head of Finance (CFO) since 1994 – interrupted by one year as Head of Finance with the Ascom Group – and a member of Senior Management since January 2004. Peter Germann previously held a variety of management positions, his last position being Head of Finance with the Arbonia-Forster Group.

Dr Rolf Holderegger (born in 1952, Swiss citizen, Dr sc. techn., Dipl. Chem. ETH) has been a member of Senior Management since October 2009. He joined the EMS Group in 1987 as Manager of Development & Technical Service. Since then he has held various senior positions, his last position being General Manager of the Profit Center "Polyurethanes and Reactive Systems" as well as Site Manager in Romanshorn, Switzerland, within the Business Unit EMS-EFTEC. Before 1987 Dr Holderegger held various leading positions with the Dow Chemical Company.

Members of Senior Management are nominated by the CEO and appointed by the Board of Directors. They are subordinate to the CEO, whom they assist in the task of managing and supervising the EMS Group. Senior Management usually meets every two weeks. In addition, the Secretary General attends these meetings in an advisory capacity. The duties and responsibilities of Senior Management are listed in section 3.5. They are also given in the Organisational Rules of Senior Management at www.ems-group.com/annualreport/2010/ organisationalrules.

4.3 Management contracts

No management contracts with third parties exist.

5. Compensation, shareholdings and loans

5.1 Content and method of determining the compensation and the shareholding programmes

The compensation system for members of the Board of Directors and Senior Management consists of a basic salary and a variable salary component, which are paid out in cash only. The basic salary and variable salary component are independent of each other. The variable salary component forms a central part of the overall compensation package. The principal criteria for setting the variable salary component are the achievement of net earnings targets and project objectives. Otherwise, no guidelines exist for the compensation system. If targets are not achieved, the variable salary component may be omitted. The level of the compensation depends on the level of objective target and the individual's responsibilities.

Individual overall compensation packages are proposed by the Compensation Committee and approved by the Chairman of the Board of Directors, after consultation with the CEO, in April of the following year. They are paid out in May.

EMS has no shareholding programmes.

Details of the individual compensation for members of the Board of Directors and CEO, and of the overall compensation paid to the Board of Directors and Senior Management as a whole, are shown in a table in note 10 to the annual financial statements of EMS-CHEMIE HOLDING AG.

6. Shareholders' participation

Shareholders' participation rights are laid down in the Articles of Association of EMS-CHEMIE HOLDING AG (www.ems-group.com/ annualreport/2010/articlesofassociation).

6.1 Voting-rights and representation restrictions

Voting-right restrictions apply solely to nominees. No rules exist governing the granting of exceptions. A registered shareholder may only be represented at the Annual General Meeting by his/her legal representative, by another shareholder who has voting rights, by the representative of the executive bodies, by the independent proxy, or by a representative of the custodian bank. Shares held by the company do not confer voting rights at the Annual General Meeting and do not bear a dividend.

6.2 Statutory quorums

Unless not otherwise provided by law, the General Meeting of Shareholders shall pass resolutions and hold elections on the basis of an absolute majority of the votes casted. In the event of a tie, the Chairman has the casting vote.

6.3 Convocation of the General Meeting of Shareholders

The Ordinary Annual General Meeting of Shareholders is convened in accordance with legal requirements and the company's Articles of Association. It is convened by publication of a single notice in the Swiss Official Gazette of Commerce (SHAB) and selected Swiss newspapers, and by written invitations sent to the addresses of the shareholders and beneficiaries entered in the share register. The period of notice is 20 days. Extraordinary General Meetings of Shareholders are held in the cases prescribed by law and as required.

6.4 Agenda

One or more shareholders representing together 10% or more of the company's shares may request that a particular item be added to the agenda. A request to add an item to the agenda must be submitted in writing at least 40 days in advance of the Annual General Meeting, specifying the subject to be discussed and containing the proposed motions.

6.5 Inscriptions into the share register

The cut-off date for entering registered shareholders in the share register with regard to participation at the General Meeting of Shareholders is around 10 calendar days before the General Meeting. The cut-off date will in each case be determined by the Board of Directors and is stated in the invitation. Registered shares sold between the cut-off date and the General Meeting of Shareholders do not carry any voting rights. There are no rules governing the granting of exceptions.

7. Changes in control and defence measures

7.1 Duty to make an offer

According to Article 3, paragraph 2 of the Articles of Association, a party acquiring shares in EMS-CHEMIE HOLDING AG is not obliged to submit a public purchase offer.

7.2 Clauses on changes of control

There are no clauses relating to changes in control.

8. Auditors

8.1 Duration of the mandate and term of office of the lead auditor

KPMG AG, Badenerstrasse 172, 8026 Zurich, Switzerland, has acted as the statutory auditor of EMS-CHEMIE HOLDING AG since 2004. The statutory auditor is appointed by the Annual General Meeting for a one-year term of office. Hanspeter Stocker has been the lead auditor since 2004. The person, leading the revision, is allowed to execute the mandate for seven years at the longest (art. 730a par. 2 CO).

8.2 Auditing fees

The EMS Group paid KPMG a global total of approximately CHF 430 000 for services relating to the audit of the Group's annual financial statements. The net sales revenue audited by KPMG accounts for approximately 67% of the EMS Group's total net sales.

8.3 Additional fees

KPMG charged a global total of approximately CHF 678000, comprising CHF 405000 for tax consultancy services, CHF 215000 for legal consultancy services and CHF 58000 for transactionrelated advice (including due diligence).

8.4 Information tools pertaining to the external audit

The Audit Committee monitors the independence and performance of the independent statutory auditor on behalf of the Board of Directors and verifies the financial reporting of EMS. It held six meetings during the year under review. The independent statutory auditor was invited to attend two meetings. Senior Management is responsible for financial accounting and continuous financial reporting, including the internal control system. The independent statutory auditor, KPMG AG, is responsible for giving an opinion on whether the accounting records and the annual financial statements comply with Swiss law and the company's Articles of Association. KPMG AG is responsible for providing an assessment of the consolidated financial statements (income statement, statement of comprehensive income, balance sheet, changes in equity, statement of cash flows and notes), in accordance with the International Financial Reporting Standards (IFRS) published by the International Accounting Standards Board (IASB) and with Swiss law. The Audit Committee is also responsible for monitoring the relevant activities of Senior Management and the independent statutory auditor.

EMS Group Corporate Governance Annual Report 2009/2010

9. Information policy

EMS publishes quarterly net sales figures, together with a commentary on the course of business and outlook for the future. The half-year and annual financial statements are prepared in accordance with IFRS. EMS also issues ad-hoc reports on important events as and when they occur.

Calendar of events of the EMS Group

July 9, 2010: Half-year report 2010 (Media conference)

August 14, 2010: Annual General Meeting 2010 of EMS-CHEMIE HOLDING AG

End of August 2010: Definitive Half-year results 2010

October 2010: Third-quarter report 2010

February 2011: Annual results 2010 (Media conference)

April 2011: First-quarter report 2011

Further details regarding dates can be found at www.ems-group.com/annualreport/2010/ information. Subscription to ad-hoc reports received by e-mail can be made at www.ems-group.com/ annualreport/2010/contact.

Further information is available on the company website: www.ems-group.com.

If you have any further enquiries, please contact: EMS-CHEMIE HOLDING AG Fuederholzstrasse 34 8704 Herrliberg Switzerland Phone +41 44 915 70 00 Fax +41 44 915 70 02 info@ems-group.com

	Notes	2009 (CHF '000)	2008 (CHF '000)
Net sales revenue from goods and services		1 197 732	1 503 947
Inventory changes, semi-finished and finished goods		(16 595)	(31 057)
Capitalised costs and other operating income	1	66 349	56 021
Operating income		1 247 486	1 528 911
Material expenses		664 546	911010
Personnel expenses	2	195 240	216252
Depreciation and amortisation	8, 23	57 792	58 1 98
Other operating expenses	3	108 103	123 894
Operating expenses		1 025 681	1 309 354
NET OPERATING INCOME (EBIT)		221 805	219 557
Income from equity-valuation of associated companies		4 971	427
Financial income	5	34 906	67 876
Financial expenses	6	11 943	30 792
NET FINANCIAL INCOME		27 934	37 51 1
NET INCOME BEFORE TAXES		249739	257 068
Income taxes	7	28 518	41 858
NET INCOME		221 221	215210
Of which attributable to:			
Shareholders of EMS-CHEMIE HOLDING AG		216138	211 803
Non-controlling interests	16	5 083	3 407
Earnings per share in CHF:			
Basic	26	9.66	9.25
Diluted	26	9.66	9.25

Consolidated Statement of Comprehensive Income

Net income recognised in income statement		221 221	215210
Net changes in fair value, after taxes: Available-for-sale securities	15	(28 2 29)	(76 671)
Net changes from cash flow hedges, after taxes	12	(27 730)	35 539
Currency translation differences		(4140)	(10 370)
Other comprehensive income, after taxes		(60 099)	(51 502)
OTAL COMPREHENSIVE INCOME		161 122	163 708
)f which attributable to:			
Shareholders of EMS-CHEMIE HOLDING AG		156 627	159 575
Non-controlling interests	16	4 495	4133

Reference numbers indicate corresponding Notes to the Consolidated Financial Statements.

Consolidated Balance Sheet

EMS Group Consolidated Financial Statements Annual Report 2009 / 2010

	Notes	31.12.2009 (CHF '000)	31.12.2008 (CHF '000
NON-CURRENT ASSETS		569 360	595 872
Intangible assets	8	26114	30 292
Property, plant and equipment	8	499 037	515 628
Financial assets		36 696	33 775
Investments in associated companies	8	16600	14836
Other investments	8	183	183
Other non-current financial assets	8	19913	18756
Derivative financial instruments	12	644	7 783
Deferred income tax assets	7	6869	8 3 9
CURRENT ASSETS		1 1 4 1 9 3 0	1 083 555
Inventories	9	217864	24272
Accounts receivable			
Trade accounts receivable	10	203 569	170742
Income tax assets		575	3 38
Other receivables	11	35 806	4951
Securities		187163	136098
Derivative financial instruments	12	7 849	33 18
Cash and cash equivalents	13	489104	447 90
TOTAL ASSETS		1711290	1 679 42
EQUITY		1 021 724	975 30
Equity, attributable to shareholders of EMS-CHEMIE HOLDING AG		1 004 851	960 094
Share capital	14	234	23
Retained earnings and reserves		788 479	74805
Net income		216138	21180
Equity, attributable to non-controlling interests	16	16873	1520
LIABILITIES		689 566	70412
Non-current liabilities		272 547	482 92
Bonds	17	0	15420
Option component of convertible bonds		0	1093
Derivative financial instruments	12	45	
Bank loans	18	150 000	15000
Other non-current liabilities	19	22 324	1235
Deferred income tax liabilities	7	80 875	9966
Provisions	20	19303	5576
Current liabilities		417019	22119
Bonds	17	156 428	
Option component of convertible bonds		0	
Derivative financial instruments	12	104	3 0 5
Bank loans	18	7 927	1650
Trade accounts payable		98 638	7084
Income tax liabilities		39 562	3403
Provisions	20	1 903	9 59
Other current liabilities	21	112 457	8715
TOTAL EQUITY AND LIABILITIES		1711290	1 679 42

Reference numbers indicate corresponding Notes to the Consolidated Financial Statements.

Consolidated Statement of Changes in Equity

EMS Group **Consolidated Financial Statements** Annual Report 2009/2010

(CHF '000)	Share capital	Capital reserves (share premium)	Retained earnings	Treasury shares	Gains/ (losses) from securities arising from IAS 39	Hedging reserves from IAS 39	Trans- lation differences	Equity, attributable to share- holders of EMS-CHEMIE HOLDING AG	Equity, attributable to non- controlling interests	Equity
At 31.12.2006	251	2176	1 184 604	(267 873)	147 099	0	(11372)	1 054 885	47 828	1 102 713
Other comprehensive income, after taxes					(32 442)		(6 945)	(39 387)	175	(39 212)
Net income recognised in income statement			283 335					283 335	10419	293 754
Buyout of non-controlling interes	ts							0	(38 901)	(38 901)
Transactions with treasury shares (incl. converted treasury shares)		21 881		133354				155 235		155 235
Dividends paid			(194 480)					(194 480)	(2457)	(196 937)
At 31.12.2007	251	24 057	1 273 459	(134 519)	114657	0	(18317)	1 259 588	17064	1 276 652
Other comprehensive income, after taxes					(76671)	35 539	(11096)	(52 228)	726	(51 502)
Net income recognised in income statement			211803					211 803	3 407	215210
Transactions with non-controlling interests (see note 16)								0	(2 4 2 4)	(2 424)
Transactions with treasury shares (incl. converted treasury shares) (see note 14)		(1 462)		4116				2 654		2 654
Redemption of share capital (see note 14)	(17)		(299 475)					(299 492)		(299 492)
Dividends paid			(162231)					(162231)	(3 565)	(165 796)
At 31.12.2008	234	22 595	1 023 556	(130 403)	37 986	35 539	(29 413)	960 094	15 208	975 302
Other comprehensive income, after taxes					(28 229)	(27 730)	(3 552)	(59511)	(588)	(60 099)
Net income recognised in income statement			216138					216138	5 083	221 221
Dividends paid			(111 870)					(111 870)	(2830)	(114 700)
At 31.12.2009	234	22 595	1 1 27 8 24	(130 403)	9757	7 809	(32 965)	1 004 851	16873	1 021 724
Balance sheet equity ratio									2009 59.7%	2008

Capital reserves are not eligible for distribution. Retained earnings include KCHF 47 (2008: KCHF 47) not eligible for distribution. The proposal of the Board of Directors for the profit distribution of EMS-CHEMIE HOLDING AG, whose financial year closes on April 30, 2010, was communicated on February 12, 2010. On April 13, 2010 the distribution of a special dividend in addition was announced. The change in other comprehensive income and income taxes recognised directly in equity amounts to KCHF 504 (2008: KCHF - 8132) on securities, KCHF - 2356 (2008: KCHF 3019) on hedge accounting according to IAS 39 and KCHF 0 (2008: KCHF - 124) on transactions with treasury shares. The translation differences contain KCHF 0 (2008: KCHF 1 998) from IAS 21 "Net investment in a foreign operation".

For further information and data refer to page 4, "Spotlight on Share Performance".

EMS Group Consolidated Financial Statements Annual Report 2009 / 2010

Notes	2009 (CHF '000)	2008 (CHF 2000)
Net income	221 221	215210
Depreciation, amortisation and impairment of intangible assets		
and property, plant and equipment 8, 23	57 792	58198
(Profit) / loss from disposal of property, plant and equipment 3	909	5 474
Increase / (decrease) of provisions 20	(37 491)	(18233)
Increase/(decrease) of other non-current liabilities	251	(205
(Income) / loss from sale of fully consolidated companies 1	(2414)	(
(Income) / expenses from the equity-valuation of associated companies	(4971)	(427)
Unrealised currency translation (gains)/losses on foreign exchange positions	(1 420)	11 423
Change assets and liabilities of post-employment benefits, net 8, 19	(1162)	(1210
Net interest expense 5, 6	8 6 4 6	379
Dividends on available-for-sale securities 5	(2 4 2 8)	(2868
Income from sale of available-for-sale securities 5	(12028)	(10616
Expenses for income taxes 7	28 5 18	41 858
Changes in net working capital	49 344	(17 425
Taxes paid	(37 794)	(56 706
Interest paid	(6 904)	(13641)
Provisions used 20	(7835)	(2 2 6 9
CASH FLOW FROM OPERATING ACTIVITIES A	252 234	208 942
(Purchase) of intangible assets and property, plant and equipment 8	(37 562)	(63712
Disposal of intangible assets and property, plant and equipment 3, 8	820	322
(Purchase) of financial assets 8	(169)	(31
Disposal of financial assets 8	62	3 2 5 2
(Purchase) of available-for-sale securities	(141 236)	(66 6 1 6
Disposal of available-for-sale securities	73970	10912
Interest received	1 232	13809
Dividends received	4 3 4 3	5140
Cash outflow from purchase of fully consolidated companies and non-controlling interests 24	(1817)	(2642
Cash inflow from sale of fully consolidated companies	624	(
Cash inflow from non-controlling interests due to founding of fully consolidated companies 16	0	423
Cash inflow from sale of associated companies	30	(
(Increase) / decrease of interest-bearing assets	6 800	42 899
CASH FLOW FROM INVESTING ACTIVITIES B	(92 903)	41 97
Capital redemption (nominal value and premium)	0	(299 492
Dividends paid	(111 870)	(162 231
Dividends paid to non-controlling interests 16	(2 830)	(3 565
(Purchase) of treasury shares	0	(17 505
Sale of treasury shares	0	2 984
Increase in interest-bearing liabilities	6 4 6 9	161 852
(Decrease) in interest-bearing liabilities	(8 2 4 4)	(214 990
CASH FLOW FROM FINANCING ACTIVITIES C	(116 475)	(532 947
TRANSLATION DIFFERENCE ON CASH AND CASH EQUIVALENTS D	(1 652)	1619
INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A + B + C + D)	41 204	(265 839
Cash and cash equivalents at 1.1.	447 900	713739
Increase / (decrease) of cash and cash equivalents	41 204	(265 839
Cash and cash equivalents at 31.12.	489104	447 900

Reference numbers indicate corresponding Notes to the Consolidated Financial Statements.

Consolidated accounting principles

General information on the consolidated financial statements

The consolidated financial statements give a true and fair view of the financial position, the results of operations and the cash flows of the EMS Group. The consolidation is based on individual financial statements of subsidiaries prepared according to uniform Group accounting principles and in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They also comply with Swiss law.

The preparation of consolidated financial statements and related disclosures in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the financial statements in the period in which they are determined to be necessary.

Changes to the consolidated accounting principles

The IASB published a series of new and revised standards and interpretations, which took effect in financial year 2009 and were implemented by the EMS Group on January 1, 2009. This has no material effect on the consolidated financial statements of the EMS Group.

IAS 1 (revised) "Presentation of Financial Statements" requires among other things additional disclosure of the statement of comprehensive income. EMS Group has opted for separate disclosure of the calculation of total comprehensive income.

IFRS 8 "Operating Segments": Internal reporting to the Board of Directors (= Chief Operating Decision Maker) is based on the two business areas of "Performance Polymers" and "Fine Chemicals / Engineering". The same accounting principles are applied as for the consolidated financial statements. Since January 1, 2009 the EMS-GRILTECH business unit has been included in the "Fine Chemicals / Engineering" business area. The segment information for the previous year was adjusted accordingly. This adjustment concerns disclosures only, and has no effect on the consolidated financial statements of the EMS Group.

The following change was made in relation to valuation principle from the previous year: IAS 19 "Employee Benefits": EMS Group decided to change the amortisation period for the recognition of actuarial losses from two years to employees' average service life. This change is a consequence of the development of unrecognised actuarial gains and losses (see note 2).

Consistency

The principles of valuation and consolidation remain unchanged from the previous year, with the exception of the changes described above. For comparative purposes, certain prior-year amounts have been reclassified and amended to conform to the current year consolidated financial statements.

Scope of consolidation

The scope of consolidation includes all companies in and outside Switzerland which are controlled – directly or indirectly – by EMS-CHEMIE HOLDING AG, holding more than 50% of the voting rights, or by contracts or other agreements (see note 30 "List of subsidiaries and non-controlling interests").

The equity method of accounting is applied for the associated companies, which are not directly or indirectly controlled by EMS-CHEMIE HOLDING AG (shareholding normally between 20% and 50% of voting rights).

Shares in other companies (less than 20% of voting rights) are valued at their fair value.

Standards that have been approved but not yet applied

The following new and revised standards and interpretations, as they are relevant for the EMS Group, were approved but do not come into effect until a later date and were not applied early in the present consolidated financial statements.

Standard/Interpretation		Entry into force	Planned application by the EMS Group
IAS 39 rev. – Financial instruments: Recognition and Measurement – Amendments for Eligible Hedged Items	*	July 1, 2009	Financial year 2010
IFRS 3 rev. – Business Combinations	***	July 1, 2009	Financial year 2010
IFRIC 17 – Distributions of Non-cash Assets to Owners	*	July 1, 2009	Financial year 2010
IAS 27 rev. – Consolidated and Separate Financial Statements	***	July 1, 2009	Financial year 2010
Improvements to IFRSs (April 2009)	*	July 1, 2009 January 1, 2010	Financial year 2010
IFRIC 14 rev. – IAS 19: The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction	*	January 1, 2011	Financial year 2011
IFRS 9 – Financial Instruments: Classification and Measurement	**	January 1, 2013	Financial year 2013

* There are not expected to be any significant implications for the consolidated financial statements of the EMS Group.

** The effects on the consolidated financial statements of the EMS Group cannot yet be sufficiently determined.

*** These Standards will have an effect on transactions effective on or after January 1, 2010.

Method of consolidation

The financial statements of majority-owned companies are fully consolidated. Assets and liabilities, income and expenses are incorporated in full. Capital consolidation is effected using the purchase method. Intercompany transactions and relations have been eliminated in the course of consolidation. Unrealised profits from intercompany deliveries are eliminated in the income statement. All assets and liabilities of acquired companies are valued according to the accounting principles of the EMS Group at the time of acquisition. Any positive difference between the resulting fair value of shareholders' equity and the cost of acquisition is capitalised as goodwill. Results for acquired companies are included in consolidation as from the date on which control was transferred.

Upon the acquisition of non-controlling interests in a fully consolidated company, any difference between the purchase price and the carrying amount of such non-controlling interests at the time of acquisition is capitalised as goodwill. No fair value adjustments are recognised. In case of disposal of companies the deconsolidation is effected through the income statement from the date control is relinquished, whereby the companies' results are included in the consolidation up to such date.

Balance sheet date

The balance sheet date of subsidiaries is December 31. The balance sheet date of EMS-CHEMIE HOLDING AG is April 30. In accordance with uniform Group accounting principles an interim closing is prepared for the holding company as of December 31.

Valuation principles

The consolidated financial statements are based on historical costs except for securities, other investments and derivative financial instruments, which are valued at fair value, as well as bonds, which are measured at amortised cost.

Intangible assets (excluding goodwill)

This item consists of acquired patents, trademarks, software and other intangible assets. Other intangible assets are measured at cost less amortisation and impairments. Amortisation of patents, trademarks and software is calculated using the straight-line method based on their limited useful economic lives, generally over 3 to 12 years.

Goodwill

This item consists of goodwill acquired in a business combination. Goodwill represents the difference between consideration paid and the fair value of the net assets and contingent liabilities acquired. Goodwill is subject to an annual impairment test.

Property, plant and equipment

Property, plant and equipment are shown at purchase price or manufacturing cost less depreciation and impairments. Assets are depreciated using the straight-line method over their estimated useful lives. Useful lives are estimated in terms of the asset's physical life expectancy, corporate policy on asset renewals and technological and commercial obsolescence. The value of the capitalised property, plant and equipment is periodically reviewed. An impairment loss is recorded when the carrying amount exceeds the recoverable amount.

Repairs and maintenance are expensed as incurred. Investments in improvements or renewals of assets are capitalised if they significantly extend service life, increase capacity or provide a substantial improvement in the quality of production performance.

Depreciation periods are as follows:

- Land: normally not depreciated
- Plant under construction: normally not depreciated
- Buildings: 25-50 years
- Technical plant and machinery: 7–25 years
- Other property, plant and equipment: 5-15 years

Leases

There are no assets held under leasing agreements which may be considered as an asset purchase in economic terms (finance lease) in the EMS Group. Payments on leased assets defined as "operating lease" and having a rental character are expensed over the lease period.

Financial assets within non-current assets

Shares in associated companies are included using the equity method.

Other investments are classified as available-forsale. The valuation is the same as described under "securities".

Inventories

Inventories used for production are valued at their historical purchase or production cost or at their net realisable value, whichever is lower. Inventories are valued using the "fifo" (first-in, first-out) method. Besides individual costs, the cost of production also includes a proportionate allocation of manufacturing overheads.

Accounts receivable

This item is measured on the basis of the original invoiced amount less allowances for doubtful accounts. Such allowances are formed if there are objective indications that outstanding amounts will not or only partially be collected. The allowance represents the difference between the invoiced amount and the recoverable amount.

Securities

Securities include marketable securities traded on stock exchanges and are classified as availablefor-sale. Initial measurement of all security transactions is done at the date of fulfillment of the contract (settlement date accounting) at fair value including transaction costs. Subsequent measurement is done at fair value with changes recorded in equity and only transferred to the income statement at the moment of the sale or in case of an impairment. Impairment is assumed when there is a significant or prolonged decline in the fair value below its cost. According to the guidelines of the EMS Group a significant or prolonged decline exists if the fair value of securities is below its cost for a period of nine months or by more than 20%. If the decline in fair value is less than 20% or lasts less than nine months, management decides whether the loss has to be considered permanent.

Cash and cash equivalents

Cash and cash equivalents include cash on hand, bank account balances and short or medium-term deposits maturing within three months. Cash and cash equivalents are valued at their nominal value.

This definition is also used for the cash flow statement.

Bonds and non-current bank loans

Convertible bonds are split into a liability component and an option component at date of issue and are shown separately in the balance sheet. On initial recognition, the fair value of the liability component is the present value of the contractually determined stream of future cash flows discounted at the rate of interest applied at that time by the market to instruments of comparable credit status and providing substantially the same cash flows, on the terms, but without the conversion option. At date of issue the value of the option component results by deduction of the liability component from the proceeds of the bond issue. With conventional convertible bonds, the holder acquires the right to convert into shares of the issuer. The option therefore constitutes an equity component. In the case of the convertible bond issued by the EMS Group, there is an option to convert into registered shares of Lonza Group AG. The option component is therefore treated as a debt instrument, and is measured at fair value in subsequent years and adjusted through the income statement. The valuation of the option component is based on the Black-Scholes model.

Non-current bank loans are recognised initially at the proceeds received, net of transaction costs incurred. In subsequent periods, non-current bank loans are stated at amortised cost.

Bonds and non-current bank loans are classified as current if they are due to be repaid within twelve months after the balance sheet closing date, even if an agreement has been concluded on the long-term refinancing or rescheduling of payment commitments after the balance sheet closing date but prior to the approval of the financial results for publication.

Liabilities and deferred income

This item includes current and non-current debts, valued at the amount of repayment, and deferred income.

Provisions

Provisions are set up for legal or other liabilities if these liabilities resulting from a past event and existing at balance sheet date will most probably bring about a cash outflow and if the amounts can be reliably estimated. A provision is recognised when the probability is above 50%. Such a provision is valued in accordance with management's best estimate of the weighted possibility. If the effect is material, provisions are determined by discounting expected future cash flows at a pretax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Employee benefits

All subsidiaries in Switzerland have their own, legally independent pension plans that are independently managed. They are financed through contributions from employers and employees. Present and former employees (or their surviving dependants) will receive benefits upon reaching the age limit and/or in the event of incapacity or death. For the purposes of the consolidated financial statements, future pension obligations are calculated on the basis of actuarial methods complying with IFRS. In the case of defined benefit obligations, the present value of the projected benefit obligation is assessed using the projected unit credit method on the basis of completed and expected years of service, the expected pay trend and the adjustment of pensions. Costs for this provision ("expense recognised in the income statement") are calculated annually and carried to the income statement. Changes in actuarial assumptions are recognised in the income statement on a straight-line basis over employees' average service life when they exceed the limit of 10% of the plan assets or 10% of the plan obligations. Employees of subsidiaries abroad are insured by governmental institutions or independent defined contribution pension plans.

Derivative financial instruments

Initial measurement of all derivative financial instruments is done at the date of transaction (trade date accounting) at fair value excluding transaction costs. Subsequent measurement is done at fair value within the balance sheet position derivative financial instruments. Changes in fair value are shown within the financial income.

Hedge accounting

Hedge accounting as defined by IAS 39 is used for the hedging of currency risks. This includes the use of cash flow hedges, which hedge future purchases and sales in foreign currencies with a high likelihood of occurrence. At initial recognition of cash flow hedges, the effective portion of hedging instruments is recognised in equity and the ineffective portion immediately in the income statement. Gains and losses from cash flow hedges shown in equity are transferred to the income statement on the date on which the forecasted transaction affects the income statement.

The goal of hedge accounting is to match the impact of the hedged item and the hedging instrument in the income statement.

Net sales revenue

Billings for goods and services are recognised as sales when the main risks and benefits incidental to ownership are transferred. Net sales revenue is stated after deduction of value added taxes and any deduction of discounts and credits.

Research and development costs

Research and development costs are charged to the income statement for the year in which they incur under the following headings: wages and salaries, material expenses and amortisation on research and development assets. Development costs are capitalised only and insofar as it can be assumed with a high degree of probability that sufficient future income will be generated to cover the costs arising in connection with the development of the product or process.

Impairment

The carrying amounts of non-current assets not valued at fair value are reviewed at balance sheet date. If there are any indications of permanent impairment, the recoverable amount is determined. The recoverable amount corresponds to the higher of the net selling price or the value in use. In cases where the carrying amount is higher than the recoverable amount, the difference is booked in the income statement.

For the impairment test the corporate assets are collected at the lowest level, for which cash flows can identified separately (cash-generating units). For estimating the value in use, the future cash flows are discounted to the present value with a discount rate before taxes which includes the current market expectations, the time value of money and the specific risks of the assets.

Fair values

The carrying amounts for securities and financial assets stated at fair value are calculated at stockexchange prices applicable on the balance sheet date. Values for derivative financial instruments are based on replacement values or recognised valuation models such as option price models (Black-Scholes). If there is no separate disclosure in the notes to the consolidated financial statements of the EMS Group, the fair values are considered to be in line with the carrying amounts at the balance sheet date.

Foreign currencies

The financial statements of the individual Group companies are presented in the currency of the primary economic environment in which the respective company operates (functional currency). The consolidated financial statements are prepared in Swiss francs, the Group's reporting currency.

Financial statements in foreign currencies are translated as follows: current assets, non-current assets and liabilities at year-end exchange rates. All items in the income statement and the net income are translated using the average exchange rate for the year. The exchange rate differences are carried to equity without affecting net income (translation adjustment).

In case of disposal of a subsidiary abroad, the translation difference, accumulated during the period when the subsidiary was a consolidated company, is added to profit (or loss) from sale of this company.

The foreign currency positions in the financial statements of the consolidated companies are translated as follows: Foreign currency transactions are translated at the exchange rate of the transaction day. At year-end the balances of monetary foreign currencies are translated at the exchange rate prevailing at year-end. The differences are recognised in the income statement (transaction gains and losses).

The most important exchange rates are:

				Average exchange rates		ear-end je rates
		Unit	2009	2009 2008		2008
Euro	EUR	1	1.510	1.586	1.488	1.490
US Dollar	USD	1	1.086	1.082	1.030	1.055
Japanese Yen	JPY	100	1.160	1.050	1.120	1.170
Chinese Renminbi	CNY	100	15.93	15.58	15.09	15.47
Taiwan Dollar	TWD	100	3.283	3.428	3.208	3.216

Income taxes

Provisions for deferred income taxes are recognised to reflect the tax impact on differences in the valuation of assets and liabilities for Group consolidation purposes and for local taxation purposes. These provisions are continuously adjusted to take account of any changes to local fiscal law. Provisions for deferred taxation are set up using the balance sheet liability method, under which deferred tax assets or liabilities are set up for all temporary differences between the tax values and the values entered in the consolidated financial statements. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised.

Earnings per share

Earnings per share are based on the consolidated net income attributable to the shareholders of EMS-CHEMIE HOLDING AG, which is divided by the weighted average number of shares issued. The diluted earnings per share figure additionally includes all the shares that could potentially be issued following the exercising of option or conversion rights, for instance.

Segment reporting

Internal reporting to the Board of Directors (= Chief Operating Decision Maker) is based on the two business areas of "Performance Polymers" and "Fine Chemicals / Engineering". The same accounting principles are applied as for the consolidated financial statements.

The strategy, and therefore the allocation of resources, is decided by the Board of Directors. The yearly budgets and medium-term plans of the two business areas are approved by the Board of Directors. The operative performance is controlled by the Board of Directors quarterly. The segmentation is prepared to the level of EBIT. A splitting of financial income and expenses and of taxes is not useful because those functions are executed on Group level. All assets and liabilities are contributed to the business area or geographical region either direct or via useful rate assessment.

Financial risk management

General

Risk management constitutes an integral part of planning and reporting activities at the EMS Group. At Senior Management and Business Unit level, risks are identified annually as part of medium-term planning procedure and preparation of the budget for the following year. They are then weighted according to the risk level and probability of its occurrence. In the course of planning discussions, the CEO and CFO report to the Board of Directors on the magnitude of these risks and the implementation status of the measures taken to counter them. The policy for the risk management remains unchanged from the previous year.

The EMS Group is exposed to various financial risks arising from its business activities such as credit risks, liquidity risks and market risks. The financial risks are reported monthly to the Board of Directors. The specific financial risks are described below.

Credit risks

Credit risks arise from the possibility that the counterparty to a transaction may be unable or unwilling to meet their obligations. Fixed-term deposits and derivative financial instruments are only entered into with counterparties that have a high credit standing. Trade receivables are subject to a policy of active risk management focusing on the assessment of country risk, credit availability, ongoing evaluation of credit standing and account monitoring procedures. There are no significant concentrations within counterparty credit risks. Within trade receivables, this is due to the EMS Group's large number of customers and their wide geographical spread, which has been permanently verified. Country risk limits and exposures are continuously monitored. The exposure of other financial assets to credit risk is controlled by setting a policy for limiting credit exposure to high-quality counterparties, ongoing reviews of credit ratings, and limiting individual aggregate credit exposure accordingly. There are no collateral or similar contracts.

Liquidity risks

Liquidity risk is the risk that the EMS Group will encounter difficulty in meeting the obligations associated with its financial liabilities. The cash flows and liquidity requirements of the EMS Group are supervised by central treasury. The goal is to have the liquidity required for day-to-day operations available at all times.

Market risks

Interest rate risks

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Currency risks

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The EMS Group operates internationally and is exposed to exchange rate risk. The EMS Group uses partly derivative financial instruments in the usual course of business to cover the risks. The EMS Group's treasury unit conducts the trade by order of Senior Management or Head of Business Unit, monitors exposure and prepares the relevant reports, which are submitted monthly to Senior Management and the Board of Directors. The liquidity required for day-to-day operations must be available at all times.

Other price risks: securities risks

Among "other price risks" are securities risks. Available-for-sale securities and the option component of convertible bonds can be influenced by changes in fair values.

Available-for-sale securities are held for fund management purposes. The risk of loss in value is reduced by reviews prior to investing and continuous monitoring of the performance of investments and changes in their risk profile.

Capital management

The capital managed by the EMS Group consists of the consolidated equity including non-controlling interests. The EMS Group has set the following goals for the management of its capital:

- maintaining a healthy and sound balance sheet structure based on continuing values;
- ensuring the necessary financial resources to be able to make investments and acquisitions;
- achieving a return for shareholders that is appropriate to the risk;
- distribution of financial resources not required for operational business to the shareholders.

Capital is monitored on the basis of the equity ratio, which is calculated as being equity (including noncontrolling interests) as a percentage of total assets. The EMS Group aims for a balance sheet equity ratio between 40% and 60%. The balance sheet equity ratio is 59.7% as at December 31, 2009 (December 31, 2008: 58.1%). The EMS Group has no external minimum capital requirements.

Treasury shares are bought and sold on the basis of active management. The EMS Group does not have any financial covenants with minimal capital requirements.

There were no changes in the EMS Group's approach to capital management in the reporting period.

Significant estimates and assumptions made by management

Impairment of non-current assets

To ascertain whether impairment has occurred, estimates are made of the expected future cash flows arising from the use and possible disposal of such assets. Significant assumptions are made in relation to such calculations, including sales figures, margins and discounting rates. It is also possible for useful lives to be reduced, the intended use of property, plant and equipment to change, production sites to be relocated or closed, and production plants to generate lower-than-expected sales in the medium term. The carrying amounts for property, plant and equipment and intangible assets are shown in note 8.

Provisions for litigation risks and other provisions

In the course of their ordinary business operations, Group companies may be involved in legal proceedings. Provisions for litigation risks and other provisions are measured using available information on the basis of the realistically expected net cash outflow, if considered necessary. Other provisions primarily cover warranty claims arising from the sale of goods or services. Future reporting periods may therefore be affected by changes in the estimates of expected or actual cash outflows. The carrying amounts for provisions are shown in note 20.

Securities

The EMS Group has classified this item as available-for-sale, which means that fluctuations in the fair value are recognised in equity until the date of sale, provided there is no lasting impairment. The assessment as to whether impairment has occurred depends on the duration and extent of the decline based on clear criteria. However, it also requires that management makes estimates with regard to future economic developments. The fair value of securities is shown in the balance sheet.

Employee benefits

The EMS Group operates various retirement plans on behalf of its employees. In the case of defined benefit plans, statistical assumptions are made in order to estimate future developments. When parameters alter due to changes in the economic situation or different market conditions, subsequent results may differ significantly from the actuarial opinions and calculations. The carrying amounts of reported employee retirement assets and liabilities are shown in notes 8 and 19.

Taxes

Measurement of current direct and indirect tax liabilities is subject to interpretation of the tax legislation in the countries concerned. The accuracy of tax declarations and appropriateness of liabilities are judged in the context of final assessments or inspections by the tax authorities. Furthermore, the judgment as to whether tax-loss carry forwards can be capitalised requires critical assessment of their usability in terms of netting with future profits, which are dependent on numerous imponderables.

Segment information by business area

	Perform Polym		Fine Cher Engine		Elimin	ation	To	tal
(CHF '000)	2009	2008	2009	2008	2009	2008	2009	2008
Net sales revenue with third parties	986090	1 240 824	211642	263123			1 197 732	1 503 947
Net sales revenue with other segments	12	131	0	0	(12)	(131)	0	0
Total net sales revenue	986102	1 240 955	211642	263123	(12)	(131)	1 197 732	1 503 947
EBITDA	238933	236258	40664	41 497	0	0	279 597	277 755
Depreciation, amortisation and impairments ¹⁾	46690	44 434	11102	13764	0	0	57792	58198
Net operating income (EBIT)	192243	191824	29562	27733	0	0	221 805	219 557
Net financial income							27934	37511
Net income before taxes							249739	257068
Income taxes							(28518)	(41858)
Net income							221 221	215210

	Performo Polyme		Fine Chen Enginee		Non-segr assets liabiliti	/	Tot	al
(CHF '000)	2009	2008	2009	2008	2009	2008	2009	2008
Segment assets ²⁾	836890	879 500	181 533	201 093	692867	598834	1711290	1 679 427
Segment liabilities ³⁾	346647	350873	28564	21603	314355	331 649	689 566	704 125
Investments	29688	47 394	7874	16318			37562	63712
Income from equity-valuation of associated companies	4971	427	0	0			4971	427

For a description of the business areas see pages 5 - 7 ("General Information on the Financial Year").

Segment information by geographical region

		Total net sales revenue (customers)		Total net sales revenue (production)		Segment assets ²⁾	
(CHF '000)	2009	2008	2009	2008	2009	2008	
Switzerland	55 844	76146	639 247	813397	571 704	650817	
European Union (EU)	702241	892223	317660	377 212	207 643	185552	
North America	128089	174796	99268	126028	96724	96541	
Asia	243352	300248	141557	187310	142352	147683	
Others	68 206	60 5 3 4	0	0	0	0	
Subtotal segments	1 197 732	1 503 947	1 197 732	1 503 947	1018423	1 080 593	
Non-segment assets					692867	598834	
Total	1 197 732	1 503 947	1 197 732	1 503 947	1711290	1 679 427	

Invoicing and cost attribution between segments are subject to the same conditions as with third parties.

Most important customers

No single customer accounts for more than 10% of total net sales revenue.

$^{\mbox{\tiny 1)}}$ See note 8.

²⁾ Segmented assets: Assets without cash and cash equivalents, securities, fixed deposits in other current and non-current financial assets

and investments in associated companies.

³⁾ Segmented liabilities: Liabilities without current and non-current bank loans, bonds and option component of convertible bonds.

EMS Group Consolidated Financial Statements Annual Report 2009 / 2010

Consolidated Income Statement

Votes		2009 (CHF '000)	2008 (CHF '000)
1	Capitalised costs and other operating income		
	Capitalised costs Other operating income Income from sale of fully consolidated companies Income from purchase of fully consolidated companies (see note 24)	5401 58528 2414 6	10543 45478 0 0
	Total capitalised costs and other operating income	66349	56021
2	Personnel expenses		
	Wages and salaries Subcontractor salaries Expenses for defined benefit plans Legal / contractual social insurance	156900 901 6930 30509	172 905 5 348 8 413 29 586
	Total personnel expenses	195240	216252
	The change mentioned in the consolidated accounting principles in relation to valuation principle means that expenses for defined benefit plans are CHF 6.0 million lower in financial year 2009. Employee benefits		
	The following figures give an overview of the Swiss pension plans:		
	Present value of funded obligations Fair value of plan assets	(338517) 395177	(404 442) 377 919
	Surplus / (deficit) in defined benefit obligations	56 660	(26523)
	Liability for long-service leave Cash-settled share-based payment liability	0 0	0
	Total employee benefits	56660	(26523)
	Unrecognisable amount Actuarial (income) / losses, not accounted for	(13688) (28556)	(12760) 52537
	Total recognised net assets in the Group balance sheet for independent defined benefit plans	14416	13254
	There are no unfunded obligations. The Group makes contributions to a contributory defined benefit plan that provides pensions for employees upon retirement, disability and death. The plan entitles a retired employee to receive an annual payment equal to 6.8% (2008: 6.8%) of the retirement assets. Disability and death pensions are defined as fixed ratios of the salary insured.		

	2009 (CHF '000)	20 (CHF '00
The balance sheet shows the following:		
Surplus recognised in financial assets as pension assets (see note 8) Deficit recognised in other non-current liabilities as liabilities	18822	1799
from employee benefits (see note 19)	(4 406)	(473
Total recognised net assets in the Group balance sheet	14416	1325
Plan assets consist of the following:		
Loans to the employer	2624	427
Liquid assets	102870	23828
Real estate	87698	2118
Bonds	31012	7502
Other equities	170973	3913
Total plan assets	395177	3779
Movement in the liability for defined benefit obligations		
Liability for defined benefit obligations at 1.1.	404 442	4537
Benefits paid by the plan	(22201)	(1689
Current service costs and interest (see below)	23814	32.2
Effect of curtailments	29	8
Settlements Actuarial (gains) / losses (see next page)	(7015) (60552)	(1119 (5431
Liability for defined benefit obligations at 31.12.	338517	404 4
	00001/	1011
Movement in plan assets		
Fair value of plan assets at 1.1.	377919	43719
Contributions paid into the plan	14060	1730
Benefits paid by the plan	(22201)	(1689
Expected return on plan assets Settlements	13226	1748
Settlements Actuarial gains / (losses) (see next page)	(7015) 19188	(1119 (6598
Fair value of plan assets at 31.12.	395177	3779
Expense recognised in the income statement		
Current service costs	13090	1793
Interest on obligation	10724	142
Expected return on plan assets	(13226)	(1748
Recognised actuarial gains and losses (see next page) Effect of curtailments	1 353 29	310 89
Effect of the limit in paragraph 58(b)	29 928	(264
Employees' contributions	(5968)	(768
ERIS (Expense Recognised in the Income Statement)	6930	84
The expense is recognised in personnel expenses.		

				2009 (CHF '000)	2008 (CHF '000)
Change of recognised net assets					
At 1.1. ERIS (Expense Recognised in the Inco Employer's contribution	ome Statement)			13254 (6930) 8092	12044 (8413 9623
At 31.12.				14416	13254
Actual return on plan assets				29042	(39054
Not recognised actuarial (gains)/los	sses				
Cumulative amount at 1.1. Actuarial (gains) / losses of the period Amortisation during the period	b			52537 (79740) (1353)	43 969 11 67 (3 103
Cumulative amount at 31.12.				(28 556)	52537
Actuarial assumptions					
(expressed as weighted averages): Discount rate at 31.12. Expected return on plan assets at 1.1 Future salary increases Future pension increases				3.3% 3.5% 1.0% 0.5%	3.5% 4.0% 1.5% 0.5%
The expected long-term rate of return a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are n	eturns on individua rns, without adjustr	l asset categ ments.	ories.		
a whole and not on the sum of the re The return is based on historical retur	eturns on individua rns, without adjustr	l asset categ ments.	ories. 2007	2006	200!
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are r	eturns on individua rns, without adjustr not paid to employ	l asset categ nents. /ees.		2006 (448 396) 423 887	(429733
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are r Historical information Present value of the defined benefit obligation	eturns on individua rns, without adjustr not paid to employ 2009 (338517)	l asset categ nents. /ees. 2008 (404442)	2007 (453718)	(448 396)	200: (429 733 402 356 (27 377
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are n Historical information Present value of the defined benefit obligation Fair value of plan assets	eturns on individua rns, without adjustr not paid to employ 2009 (338517) 395177	l asset categ nents. yees. 2008 (404442) 377919	2007 (453718) 437196	(448 396) 423 887	(429 733 402 35
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are r Historical information Present value of the defined benefit obligation Fair value of plan assets Surplus/(deficit) in defined benefit obligations Experience gains/(losses) arising on plan liabilities	eturns on individua rns, without adjustr not paid to employ (338517) 395177 56660 59789 19188	l asset categ ments. /ees. 2008 (404442) 377919 (26523) (16177) (65988)	2007 (453718) 437196 (16522) 1901 (1138)	(448 396) 423 887 (24 509) (5 381)	(429 733 402 35 (27 377
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are Historical information Present value of the defined benefit obligation Fair value of plan assets Surplus/(deficit) in defined benefit obligations Experience gains/(losses) arising on plan liabilities Experience gains/(losses) arising on plan assets	eturns on individua rns, without adjustr not paid to employ (338517) 395177 56660 59789 19188	l asset categ ments. /ees. 2008 (404442) 377919 (26523) (16177) (65988)	2007 (453718) 437196 (16522) 1901 (1138)	(448 396) 423 887 (24 509) (5 381)	(429 733 402 35 (27 377
a whole and not on the sum of the re The return is based on historical retur In Switzerland health care costs are r Historical information Present value of the defined benefit obligation Fair value of plan assets Surplus/(deficit) in defined benefit obligations Experience gains/(losses) arising on plan liabilities Experience gains/(losses) arising on plan assets The Group expects to pay KCHF 7264 (2009: KCHF 80	eturns on individua rns, without adjustr not paid to employ (338517) 395177 56660 59789 19188	l asset categ nents. /ees. 2008 (404442) 377919 (26523) (16177) (65988) ned benefit plans in	2007 (453718) 437196 (16522) 1901 (1138)	(448 396) 423 887 (24 509) (5 381)	(429 733 402 35 (27 37)

4

Research and development		
Expenditures for research and development amount to In percent of net sales revenue	39149 3.3%	48 155 3.2%

otes		2009 (CHF '000)	2008 (CHF '000)
-)	Financial income		
	Interest income from related parties Other interest income Interest income on loans and receivables Interest income on held-to-maturity investments Total interest income	0 1212 5 0 1217 2428	36 11490 57 12433
	Dividends on available-for-sale securities Foreign exchange gains, net Income from sale of available-for-sale securities, net Fair value adjustments on derivative financial instruments, net Income from conversion of bonds Income from repurchase of own bonds	8300 12028 10933 0 0	286 1061 3464 598 133
	Total financial income	34 906	67870
)	Financial expenses		
	Interest expenses to associated companies Other interest expenses Interest expenses on financial liabilities measured at amortised cost Total interest expenses Foreign exchange losses, net Bank charges and commissions	82 3546 <u>6235</u> 9863 0 2080	75 1 247 <u>11 492</u> 12 814 16 500 1 478
	Total financial expenses	11943	30792
7	Income taxes		
	Current income taxes Deferred income taxes	45999 (17481)	34 497 7 36
	Total income taxes	28518	41858
	The ultimate holding company is incorporated in Switzerland. The subsidiaries operate in different countries with different tax laws and tax rates. The expected income tax rate corresponds to the weighted average of the tax rates in the tax jurisdictions in which the EMS Group operates. Due to the mix of the EMS Group's taxable income and changes in some local tax rates, the expected income tax rate changes from year to year. The effective income tax expenses differed from the expected income tax expenses as follows:		
	Breakdown of the income tax expenses		
	Net income before income taxes Expected income tax rate Expected income taxes	249739 17.1% 42724	257 068 21.0% 54 083
	Use of tax losses carried forward not capitalised Change in deferred tax assets not having been set up Tax exemption / Expenses not being deductible for tax purposes Taxes from previous years and tax holidays Impact of changed deferred income tax rates Other	(2751) 2946 (1754) (5007) (7705) 65	(1 122 (2 764 (1 294 (7 031 (172 15
	Effective income taxes Effective income tax rate	28518 11.4%	4185 16.3%

EMS Group Consolidated Financial Statements Annual Report 2009 / 2010

	20 (CHF '00		20 (CHF '00	
Deferred income taxes: Change in recognised assets / liabilities				
	Deferred income tax assets	Deferred income tax liabilities	Deferred income tax assets	Deferred incom tax liabilitie
 At 1.1.	8 3 9 4	99666	12403	105 029
Change in scope of consolidation	216	0	0	(
Increase via income statement	1 882	729	45	849
Decrease via income statement	(3627)	(19955)	(3808)	(4900
Income taxes recognised directly in equity	0	504	0	(8132
Translation differences	4	(69)	(246)	(829
At 31.12.	6869	80875	8 3 9 4	99660
Note to the deferred income tax liabilities				
Calculation according to the "balance sheet liability method": Deferred income taxes on non-current assets Deferred income taxes on current assets Deferred income taxes on liabilities	665 107 35		7667 2068 231	33
Total deferred income tax liabilities	808	375	9966	66
Deferred income taxes on non-current assets affect mainly property, plant and equipment, on current assets inventories.				
Tax loss carryforwards				
	Tax loss carryforwards	Tax effect	Tax loss carryforwards	Tax effe
Total tax loss carryforwards not considered				
in the balance sheet	52922	17612	41519	1201
Of which to be carried forward for up to:				
l year	0	0	0	
2 years	0	0	0	(
3 years	0	0	0	(
4 years	6957	1391	159	3
5 years	0	0	10136	212
More than 5 years	45965	16221	31224	985

8 Intangible assets, property, plant and equipment, financial assets

I. Intangible assets				
(CHF '000)	Goodwill	Patents, trade- marks	Others	Total
At 1.1.2008				
Cost	17983	13297	26 0 26	57306
Accumulated amortisation and impairment	0	(12164)	(12103)	(24267)
Net book value	17983	1133	13923	33039
2008				
At 1.1.	17983	1133	13923	33039
Additions	3161	49	570	3780
Disposals	0	0	(72)	(72)
Amortisation	0	(938)	(5001)	(5939)
Reclassifications	0	Ś	651	` 656
Translation differences	(422)	(50)	(700)	(1172)
At 31.12.	20722	199	9371	30292
Cost	20722	4088	24 645	49455
Accumulated amortisation and impairment	0	(3889)	(15274)	(19163)
Net book value	20722	199	9371	30292
2009				
At 1.1.	20722	199	9371	30292
Change in scope of consolidation	0	0	5	5
Additions	0	66	195	261
Disposals	0	(60)	(28)	(88)
Amortisation	0	(75)	(4 4 34)	(4 509)
Reclassifications	0	Ó	328	328
Translation differences	(197)	3	19	(175)
At 31.12.	20525	133	5456	26114
Cost	20525	253	24 559	45337
Accumulated amortisation and impairment	0	(120)	(19103)	(19223)
Net book value	20525	133	5456	26114

The other intangible assets mainly contain customer related intangibles and capitalised software usage rights.

The addition in goodwill results from the buyout of the minorities at Changchun EFTEC Chemicals Products Ltd. as at January 1, 2008 (see note 16) and concerns the segment "Performance Polymers".

Impairment test for goodwill:

The cash generating unit for the impairment test of the total goodwill of KCHF 20525 (2008: KCHF 20722) is the Business Unit EMS-EFTEC (segment "Performance Polymers"). Its recoverability is tested yearly on the basis of future cash flows. The recoverable amount calculated by impairment testing is based on the value in use.

The following assumptions form the basis:

- The cash flows for the first three years were determined on the basis of medium-term plans.

- The cash flows of the following years were calculated with an annual growth rate of 1%.

- The discount rate before taxes is 11%.

The projections are based on knowledge and experience and also on judgements made by management as to the probable economic development of the relevant markets.

Impairment testing as of the closing date confirmed the recoverability of goodwill.

CHF 7000) cost RED plants rehides At 1.1.2008 20456 293 374 802 688 60787 60011 123731 Accmuluted depreciation and impairment (1387) (168869) (504 764) (40896) 0 (71591) Net book value 19069 124 505 297 924 19891 60011 521 44 2008 At 1.1. 19069 124 505 297 924 19891 60011 521 44 Additions 67 607 3133 1976 57310 6300 Disposals (352) (3541) (1403) (422) (6) (572) Depreciation (66 (6684) (32 447) (4415) 0 (4561) Impairment 0 0 (6288) (143) (216) (664) Reclassifications 803 22994 48044 2875 (75482) (76 Cost 20156 300 628 844057 60398 41538 5156. <	Land incl.	Buildings	Technical plant,	Furniture, EDP	Plant under construction	Total
Cost 20456 293374 802688 60787 60011 123731 Accumulated depreciation and impairment (1387) (168869) (504764) (40896) 0 (71591) Net book value 19069 124505 297924 19891 60011 52140 2008 11.1. 19069 124505 297924 19891 60011 52140 Additions 67 607 3133 1976 57310 6300 Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (32447) (4415) 0 (4561 Redexisifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300.628 844057						
Cost 20456 293374 802688 60787 60011 123731 Accumulated depreciation and impairment (1387) (168869) (504764) (40896) 0 (71591) Net book value 19069 124505 297924 19891 60011 52140 2008 11.1. 19069 124505 297924 19891 60011 52140 Additions 67 607 3133 1976 57310 6300 Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (32447) (4415) 0 (4561 Redexisifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300.628 844057						
and impairment (1387) (168869) (504764) (40896) 0 (71591) Net book value 19069 124505 297924 19891 60011 52140 2008 At 1.1. 19069 124505 297924 19891 60011 52140 Additions 67 607 3133 1976 57310 6305 Disposals (352) (3541) (1403) (422) (6) (572) Depreciation (66) (8684) (143) (216) (664) Redassifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011 At 31.12. 18723 131617 305119 18631 41538 1566 Cost 20156 300628 844057 60398 41538 5156 Cost 20156 300628 844057 60398 41538 5156	20456	293 374	802 688	60787	60011	1 237 316
Net book value 19069 124505 297924 19891 60011 52140 2008 At 1.1. 19069 124505 297924 19891 60011 52140 2008 At 1.1. 19069 124505 297924 19891 60011 52140 Additions 67 607 3133 1976 57310 6300 Depreciation (66) (8684) (32447) (4415) 0 (4561 Impairment 0 0 62888 (143) (216) (664 Reclassifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011 At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 51562 Cost 2009 At 1.1. 18723 131617 305119 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
2008 2016 211.1. 19069 124505 297924 19891 60011 52144 Additions 67 607 3133 1976 57310 6309 Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (32447) (4415) 0 (4561 Impairment 0 0 (6288) (143) (216) (664 Redasifications 803 22994 48044 2875 (75482) (76 Ironslation differences (798) (4264) (3844) (1131) (79) (1011 At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 126677 Accumulated depreciation and impairment (1433) (169011) (538938) (41767) 0 (75114 Net book value 18723 131617 305	(1 387)	(168869)	(504 764)	(40896)	0	(715916)
At 1.1. 19069 124505 297924 19891 60011 52140 Additions 67 607 3133 1976 57310 6305 Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (3247) (4415) 0 (4561) Impairment 0 0 (6288) (143) (216) (664 Reclassifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 51562 Cost 20156 300628 844057 60398 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 21.1. 18723 131617 305119 18631	19069	124 505	297924	19891	60011	521 400
Additions 67 607 3133 1976 57310 6309 Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (32447) (4415) 0 (4561 Impoirment 0 0 (6288) (143) (216) (664 Reclassifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 126677 Accumulated depreciation 0 169011) (538938) (41767) 0 (75114 Net book value 18723 131617 305119 18631 41538 51562 Change in scope of consolidation 0 0 1953 69 411 24						
Disposals (352) (3541) (1403) (422) (6) (572 Depreciation (66) (8684) (32447) (4415) 0 (4561 Impairment 0 0 (6288) (143) (216) (664 Reclassifications 803 22994 48044 2875 (75482) (76 Iranslation differences (798) (4264) (3844) (1131) (79) (1011 At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 126677 Accumulated depreciation 0 169011) (538938) (41767) 0 (75114 Net book value 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1.1 18723 131617						521 400
Depreciation `(66) `(8684) (32447) (4415) `(0) (4561) Impairment 0 0 (6288) (143) (216) (648) Reclossifications 803 22994 48044 2875 (75482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 126672 Accumulated depreciation 1433) (169011) (538938) (41767) 0 (75114) Net book value 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 219 2053 4631 1795 27603 3733 Disposals 0 0 0 13636 (878)						63 0 9 3
Impairment Ó <thó< tr=""> 11 12<td></td><td></td><td></td><td></td><td></td><td>(5724)</td></thó<>						(5724)
Reclassifications 803 22 994 48 044 2875 (75 482) (76 Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18 723 131 617 305 119 18 631 41 538 51 562 Cost 20 156 300 628 844 057 60 398 41 538 1 266 77 Accumulated depreciation and impairment (1433) (169 011) (538 938) (41 767) 0 (751 14 Net book value 18 723 131 617 305 119 18 631 41 538 51 562 2009 2009 2009 2009 2009 2009 2009 2003 37 305 119 18 631 41 538 51 562 2009 2009 2015 4 631 1 795 27 603 37 30 Additions 1 219 2053 4 631 1 795 27 603 37 30 Disposals 0 (336) (878) (393) (34) (164 <td></td> <td>\ <i>/</i></td> <td></td> <td></td> <td>•</td> <td>(45612)</td>		\ <i>/</i>			•	(45612)
Translation differences (798) (4264) (3844) (1131) (79) (1011) At 31.12. 18723 131617 305119 18631 41538 51562 Cost 20156 300628 844057 60398 41538 126677 Accumulated depreciation and impairment (1433) (169011) (538938) (41767) 0 (75114 Net book value 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009	-	•				(6647)
At 31.12. 18723 131 617 305 119 18 631 41 538 515 62 Cost 20 156 300 628 844 057 60 398 41 538 1 266 72 Accumulated depreciation and impairment (1 433) (169 011) (538 938) (41 767) 0 (751 14) Net book value 18723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 51 562 2009 O 0 0 33 73 69 411 2						(766)
Cost 20156 300 628 844 057 60 398 41 538 1 266 77 Accumulated depreciation and impairment (1 433) (169 011) (538 938) (41 767) 0 (751 14 Net book value 18 723 131 617 305 119 18 631 41 538 51 562 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 51 562 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 51 562 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 51 562 2009 At 1.1. 18 723 131 617 305 119 18 631 41 538 51 562 2009 At 3.1.1 12 19 2053 4 631 1 795 27 603 37 30 2019 0 (336) (878) (393) (34) (164 Depreciation (69) (8021) (33917) (4088) (217) (4631 <	(798)	(4264)	(3844)	(1131)	(79)	(10116)
Accumulated depreciation and impairment (1433) (169011) (538938) (41767) 0 (75114) Net book value 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 0 0 1953 69 411 243 Additions 1219 2053 4631 1795 27603 3730 Disposals 0 (336) (878) (393) (34) (164 Depreciation (69) (8021) (33917) (4088) (217) (4631 Impairment 0 (3562) <td>18723</td> <td>131617</td> <td>305119</td> <td>18631</td> <td>41 538</td> <td>515628</td>	18723	131617	305119	18631	41 538	515628
and impairment (1433) (169011) (538938) (41767) 0 (75114) Net book value 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 2009 At 1.1. 18723 131617 305119 18631 41538 51562 Additions 0 0 1953 69 411 243 Additions 1219 2053 4631 1795 27603 3730 Disposals 0 (336) (878) (393) (34) (164) Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697 Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 <	20156	300 628	844057	60398	41 538	1 266 777
Net book value 18723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18723 131 617 305 119 18 631 41 538 515 62 2009 At 1.1. 18723 131 617 305 119 18 631 41 538 515 62 Change in scope of consolidation 0 0 1953 69 411 243 Additions 1219 2053 4 631 1795 27 603 37 30 Disposals 0 (336) (878) (393) (34) (164 Depreciation (69) (8021) (33 917) (4088) (217) (4631 Impairment 0 (3562) (3409) 0 0 (697 Reclassifications 0 13 972 11 437 990 (26 727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19 907 135 064 284 162 16 983 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
2009 At 1.1. 18723 131 617 305 119 18631 41 538 515 65 Change in scope of consolidation 0 0 1953 69 411 243 Additions 1219 2053 4631 1795 27 603 37 30 Disposals 0 (336) (878) (393) (34) (164 Depreciation (69) (8021) (33 917) (4088) (217) (46 31) Impairment 0 (3562) (3 409) 0 0 (697) Reclassifications 0 13 972 11 437 990 (26 727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284 162 16 983 42 921 49903 Cost 21 390 306 998 814023 55 903 42 921 1241 23 Accumulated depreciation (1483) (171 934) (529 861) (38 920)	(1433)	(169011)	(538938)	(41767)	0	(751 149)
At 1.1. 18723 131617 305119 18631 41538 51562 Change in scope of consolidation 0 0 1953 69 411 243 Additions 1219 2053 4631 1795 27603 3730 Disposals 0 (336) (878) (393) (34) (164 Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697 Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)	18723	131617	305119	18631	41 538	515628
Change in scope of consolidation 0 0 1953 69 411 243 Additions 1219 2053 4631 1795 27603 3730 Disposals 0 (336) (878) (393) (34) (164) Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697) Reclassifications 0 13972 11437 990 (26727) (32) Translation differences 34 (659) (774) (21) 347 (107) At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)						
Additions 1219 2053 4631 1795 27603 3730 Disposals 0 (336) (878) (393) (34) (164) Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697) Reclassifications 0 13972 11437 990 (26727) (32) Translation differences 34 (659) (774) (21) 347 (107) At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation (1483) (171934) (529861) (38920) 0 (74219)						515628
Disposals 0 (336) (878) (393) (34) (164) Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697 Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation (1483) (171934) (529861) (38920) 0 (74219)		•				2433
Depreciation (69) (8021) (33917) (4088) (217) (4631) Impairment 0 (3562) (3409) 0 0 (697 Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)						
Impairment Ó (3562) (3409) Ó Ó Ó (697 Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)						
Reclassifications 0 13972 11437 990 (26727) (32 Translation differences 34 (659) (774) (21) 347 (107 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)				(/	· /	
Translation differences 34 (659) (774) (21) 347 (1`07 At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21390 306998 814023 55903 42921 124123 Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219)	-			•	•	
At 31.12. 19907 135064 284162 16983 42921 49903 Cost 21 390 306 998 814023 55903 42 921 1 241 23 Accumulated depreciation and impairment (1483) (171 934) (529 861) (38 920) 0 (742 19)	-					
Cost 21 390 306 998 814023 55 903 42 921 1 241 25 Accumulated depreciation and impairment (1483) (171 934) (529 861) (38 920) 0 (742 19)		()	()	. ,		()
Accumulated depreciation and impairment (1483) (171934) (529861) (38920) 0 (74219	19907	135064	284162	16983	42921	499 037
and impairment (1483) (171934) (529861) (38920) 0 (74219	21 390	306 998	814023	55903	42921	1 241 235
	(1483)	(171934)	(529861)	(38920)	0	(742198)
	(/	X 7	()	· · · ·	12021	499 037
Net book value		ind. development cost 20456 (1387) 19069 67 (352) (66) 0 803 (798) 18723 20156 (1433) 18723 20156 (1433) 18723 18723 0 1219 0 (69) 0 0 (69) 0 0 34 19907 21390	ind. development cost 20456 293374 (1387) (168869) 19069 124505 19069 124505 67 607 (352) (352) (352) (3541) (66) (8684) 0 0 0 0 0 803 22994 (798) (4264) 18723 131617 20156 300628 (1433) (169011) 18723 131617 18723 131617 18723 131617 0 0 0 1219 2053 0 (336) (69) (8021) 0 (3562) 0 13972 34 (659) 19907 135064 21390 306998 (1483) (171934)	ind. plant, machinery, R&D plants 20456 293374 802688 (1387) (168869) (504764) 19069 124505 297924 67 607 3133 (352) (3541) (1403) (66) (8684) (32447) 0 0 (6288) 803 22994 48044 (798) (4264) (3844) 18723 131617 305119 20156 300628 844057 (1433) (169011) (538938) 18723 131617 305119 0 0 1953 1219 2053 4631 0 (336) (878) (69) (8021) (33917) 0 (3562) (3409) 0 (3562) (3409) 0 (3562) (3409) 0 (3562) (3409) 0 (3562) (3409) 0	ind. o plont, mechinery, RED plants EDP equipment, vehicles 20456 293374 802688 60787 (1387) (168869) (504764) (40896) 19069 124505 297924 19891 19069 124505 297924 19891 67 607 3133 1976 (352) (3541) (1403) (422) (66) (8684) (32447) (4415) 0 0 (6288) (143) 803 22994 48044 2875 (798) (4264) (3844) (1131) 18723 131 617 305119 18631 20156 300 628 844057 60398 (1433) (169011) (538938) (41767) 18723 131 617 305119 18631 0 0 1953 69 1219 2053 4631 1795 0 (336) (878) (393) <t< td=""><td>incl. orgenerit plant, machinery, R&D plants EDP equipment, vehicles construction 20456 293374 802688 60787 60011 (1387) (168869) (504764) (40896) 0 19069 124505 297924 19891 60011 (352) (3541) (1403) (422) (6) (66) (8684) (3247) (4415) 0 0 0 (6288) (143) (216) 803 22994 48044 2875 (75482) (798) (4264) (3844) (1131) (79) 18723 131617 305119 18631 41538 (1433) (169011) (538938) (41767) 0 0 0 1953 69 411 1219 2053 4631 1795 276033 0 0 1953 69 411 1219 2053 4631 1795 276033</td></t<>	incl. orgenerit plant, machinery, R&D plants EDP equipment, vehicles construction 20456 293374 802688 60787 60011 (1387) (168869) (504764) (40896) 0 19069 124505 297924 19891 60011 (352) (3541) (1403) (422) (6) (66) (8684) (3247) (4415) 0 0 0 (6288) (143) (216) 803 22994 48044 2875 (75482) (798) (4264) (3844) (1131) (79) 18723 131617 305119 18631 41538 (1433) (169011) (538938) (41767) 0 0 0 1953 69 411 1219 2053 4631 1795 276033 0 0 1953 69 411 1219 2053 4631 1795 276033

Fire insurance value is KCHF 1 552 192 (2008: KCHF 1 474 586). Property, plant and equipment are insured at replacement values.

Due to the yearly systematic review and check of usability of manufacturing line, the following impairments were booked:

Year	Amount	Segment
2009:	KCHF 6971	Performance Polymers
2008:	KCHF 6647	Performance Polymers

III. Financial assets

	Investments	Other	C	Ither non-current financia	ıl assets
	in associated	investments	Pension	Other	Tota
	companies		assets IAS 19	non-current financial assets	
(CHF '000)			IAS 19	TINANCIAI ASSETS	
At 1.1.2008					
Cost/Fair value	16934	182	17004	4 626	21630
Accumulated depreciation /					
amortisation and impairment	0	0	0	(670)	(670)
Net book value	16934	182	17004	3 956	20960
2008					
At 1.1.	16934	182	17004	3 956	20960
Additions / Increase	0	1	989	30	1019
Disposals / Decrease	(1851)	0	0	(3252)	(3252)
Translation differences	(247)	0	0	29	29
At 31.12.	14836	183	17993	763	18756
Cost/Fair value	14836	183	17993	812	18805
Accumulated depreciation /					
amortisation and impairment	0	0	0	(49)	(49)
Net book value	14836	183	17993	763	18756
2009					
At 1.1.	14 836	183	17993	763	18756
Change in scope of consolidation	0	0	0	240	240
Additions / Increase	1942	0	829	169	998
Disposals / Decrease	(49)	0	0	(62)	(62)
Translation differences	(129)	0	0	(19)	(19)
At 31.12.	16600	183	18822	1091	19913
Cost/Fair value	16600	183	18822	1133	19955
Accumulated depreciation /					
amortisation and impairment	0	0	0	(42)	(42)
Net book value	16600	183	18822	1091	19913

EMS Group Consolidated Financial Statements Annual Report 2009 / 2010

Votes		2009 (CHF '000)	2008 (CHF '000)
9	Inventories		
	Raw materials and supplies Semi-finished goods, work in progress Finished products Value adjustments	74918 9507 161068 (27629)	85720 8027 176750 (27777
	Total inventories	217864	242720
10	Trade accounts receivable		
	Trade accounts receivable from associated companies Trade accounts receivable from third parties Allowances for doubtful accounts	117 211929 (8477)	(17873) (7988
	Total trade accounts receivable	203 569	170742
	Allowances for doubtful accounts are determined on the basis of historical losses and recognisable individual risks.		
	Due dates of trade accounts receivable		
	Not due Overdue <30 days Overdue 30 to 90 days	191 299 17 163 1 768	14831
	Overdue >90 days	1816	409
	Overdue >90 days Total		409 2538
		1816	409 2538
	Total The movement of the allowances for doubtful accounts on trade accounts	1816	409 2533 178730 7789 689
	Total The movement of the allowances for doubtful accounts on trade accounts receivable is as follows: At 1.1. Increase / Decrease	1816 212046 7988 541	4 09 2 533 178 730 7 784 684 (490
11	Total The movement of the allowances for doubtful accounts on trade accounts receivable is as follows: At 1.1. Increase / Decrease Translation differences	1816 212046 7988 541 (52)	4 09 2 533 178 730 7 78 68 (490
11	Total The movement of the allowances for doubtful accounts on trade accounts receivable is as follows: At 1.1. Increase / Decrease Translation differences At 31.12.	1816 212046 7988 541 (52)	23788 409 2538 178730 7789 689 (490 7988 (490 7988 36327 13100

S				2009 (CHF '000)	200 (CHF '000
	Derivative fina	ncial instrumen [.]	ts		
	The following summary shows the most important derivative financial instruments:				
	Financial instru				
	Currency SWAPS and forward rate	EUR/CHF	Notional amount CHF Positive replacement value CHF Negative replacement value CHF	3721 3 0	3907 21 95
	agreements	JPY/CHF	Notional amount CHF Positive replacement value CHF	1 350 6 0	53
		USD/CHF	Negative replacement value CHF Notional amount CHF Positive replacement value CHF	1 193 8	38 <i>7</i> 9 70
		CZK/CHF	Negative replacement value CHF Notional amount CHF Positive replacement value CHF	0 11315 0	17 468
		AUD/CHF	Negative replacement value CHF Notional amount CHF Positive replacement value CHF	125 1395 0	13
		GBP/EUR	Negative replacement value CHF Notional amount CHF Positive replacement value CHF	20 0 0	758
	Currency options	EUR/CHF	Negative replacement value CHF Notional amount CHF Positive replacement value CHF Negative replacement value CHF	0 0 0 0	4 3027 4 29
	Total		Notional amount CHF Positive replacement value CHF Negative replacement value CHF	18974 17 145	12092 95 160
	Thereof: Currei	nt portion	Notional amount CHF (<12 months) Positive replacement value CHF	13359	12092
	N L.		(<12 months) Negative replacement value CHF (<12 months)	17 100	95 160
	INON-C	current portion	Notional amount CHF (1–5 years) Positive replacement value CHF (1–5 years)	5615 0	
			Negative replacement value CHF (1–5 years)	45	

		2009 (CHF '000)	200 (CHF '000
Financial instruments effective	ofor hedge accounting purposes		
Currency EUR/CHF SWAPS and forward rate	Notional amount CHF Positive replacement value CHF Negative replacement value CHF	115817 1332 4	296 <i>5</i> 9 1582
agreements JPY/CHF	Notional amount CHF Positive replacement value CHF	88278 7144	15597 1635
USD/CHF	Negative replacement value CHF Notional amount CHF Positive replacement value CHF	0 0 0	1 45 89 83 5 64
Currency JPY/CHF options	Negative replacement value CHF Notional amount CHF Positive replacement value CHF Negative replacement value CHF	0 0 0	2120 219
Total	Notional amount CHF Positive replacement value CHF Negative replacement value CHF	204 095 8 476 4	563.60 40.01 1.45
Thereof: Current portion	Notional amount CHF (<12 months) Positive replacement value CHF	194 445	49634
	(<12 months) Negative replacement value CHF (<12 months)	7832	3223 145
Non-current portion		9650	672
	(1–5 years) Negative replacement value CHF (1–5 years)	644 0	778
Currency SWAPS, forward ra	s were mostly effected for hedging purposes. te agreements and currency option contracts uture purchases and sales in foreign currencies.		
The replacement value is und financial instruments. Positive if the counterparty cannot de	erstood as beeing the fair value of derivative replacement values are the values that are lost iver (maximum default risk). This risk is considered parties are first-rate financial institutions.		
Net changes from cash flow hedges in equity, after taxes			
At 1.1.		35539	
Transfer to consolidated inco Fair value adjustments Income taxes recognised dire		(30775) 689 2356	38 <i>55</i> (301
Total net changes from cash t	low hedges in equity, after taxes	(27730)	35.53
At 31.12.		7809	3553
Cash and cash equivalents			
Deposits Cash and cash equivalents		488 083 1 02 1	446 48 1 4 1
Total cash and cash equivale	ents	489104	44790

	2009	2008
Notes	(CHF '000)	(CHF '000)

14 Share capital

	Par value	Number of issued registered shares	Number of treasury shares	Number of shares entitled to dividend	Share capital (CHF '000)
At 31.12.2007	CHF 0.01	25052870	1027216	24 025 654	251
Purchase of treasury shares Sale of treasury shares Repurchase of registered shar	65		132114 (9023)	(132114) 9023	-
via put options Redemption of share capital Converted treasury shares		_ (1663842)	1 663 842 (1 663 842)	(1 663 842) _	- (17)
(see note 17) At 31.12.2008	CHF 0.01	- 23 389 028	(135 190)	135190	
Purchase of treasury shares Sale of treasury shares					
At 31.12.2009	CHF 0.01	23389028	1015117	22373911	234

15 Net changes in fair value in equity, after taxes: available-for-sale securities

At l. l.	37 986	114657
Transfer into consolidated income statement Fair value adjustments Income taxes recognised directly in equity due to fair value adjustments	(1 986) (25 739) (504)	(31 168) (53 635) 8 132
Total net changes in fair value, after taxes: available-for-sale securities	(28 2 29)	(76671)
At 31.12.	9757	37 986

16 Non-controlling interests

5		
This item reflects the non-controlling interests in capital and profit/loss for the year. Minorities own significant shares in EMS-UBE Ltd., EFTEC Asia Pte. Ltd., Shanghai EFTEC Chemical Products Ltd., Wuhu EFTEC Chemical Products Ltd. (from August 31, 2008) and Changchun EFTEC Chemical Products Ltd. (until January 1, 2008). The change in non-controlling interests is as follows:		
At 1.1.	15208	17064
Founding with non-controlling interests	0	423
Buyout of non-controlling interests (see note 24)	0	(2847)
Dividends paid	(2830)	(3565)
Net income	5083	3407
Translation differences	(588)	726
At 31.12.	16873	15208

Notes		2009 (CHF '000)	2008 (CHF '000)
17	Bonds		
	Current bond: EMS-INTERNATIONAL FINANCE (Guernsey) Ltd.: 2.5% convertible bond 2002–23.4.2010	156428	_
	Total current bond	156428	-
	Non-current bond: EMS-INTERNATIONAL FINANCE (Guernsey) Ltd.: 2.5% convertible bond 2002–23.4.2010	_	154209
	Total non-current bond	-	154209
	The option component of the convertible bond is separately stated in the balance sheet. The convertible bond is stated less converted shares or shares repurchased via the stock exchange. The discount rate for the convertible bond is 4.00%. The convertible bond contains standard covenants and offers standard anti-dilution protection.		
	Details to the bond issued:		
	2.5% convertible bond 2002–23.4.2010 (nominal CHF 350 million)		
	Each bond of CHF 5000 can be converted at any time during the conversion period (23.4.2002 – 13.4.2010) into 40 registered shares of Lonza Group AG (conversion price per Lonza share: CHF 125).		
	The net present value is as follows: Present value issued bond Present value repurchased bond	348 415 (191 987)	343 428 (189 219)
	At 31.12.	156428	154 209
	Fair value at 31.12.	157533	160303
18	Bank loans		
	The non-current bank loans are composed as follows: CHF: Average interest rate: 1.90% (2008: 1.90%)	150000	150000
	Total non-current bank loans	150000	150000
	The non-current bank loans have a fixed interest rate. The fair value amounts to KCHF 151 674 (2008: KCHF 150 000). In 2008 the fair value corresponded to the carrying amount, as the bank loans were agreed in December 2008.		
	The current bank loans are composed as follows: JPY: Average interest rate: 0.73% (2008: 1.21%) CNY: Average interest rate: 5.31% (2008: 5.58%)	6720 1207	15269 1238
	Total current bank loans	7927	16507
	The carrying amounts of current bank loans correspond to their fair values, as the interest rates are variable.		

Notes		2009 (CHF '000)	2008 (CHF '000)
19	Other non-current liabilities		
	Other non-current liabilities Liabilities from employee benefits IAS 19	3737 18587	3921 8431
	Total other non-current liabilities	22324	12352
	Liabilities from employee benefits IAS 19 include KCHF 4406 (2008: KCHF 4739) liabilities from Swiss pension plans (see note 2). The increase in liabilities from employee benefits IAS 19 is mainly explained by the acquisition of EMS-CHEMIE (Neumünster) (see note 24).		

20 Provisions

(CHF '000)	Pension liabilities	Provisions for restructuring costs	Provisions for litigation risks	Other provisions	Total
At 31.12.2008	1 447	9 599	42 4 28	11 894	65368
Change in scope of consolidation	0	0	0	1124	1124
Increase via income statement	155	0	3315	369	3839
Decrease via income statement	0	(3011)	(38195)	(124)	(41 3 30)
Amounts used	(225)	(4773)	(2780)	(57)	(7835)
Translation differences	(11)	88	(11)	(26)	40
At 31.12.2009	1 366	1 903	4757	13180	21 206
Of which: Current portion of provisions	0	1 903	0	0	1 903
Non-current portion of provisions	1 366	0	4757	13180	19303

<u>Pension liabilities</u> mainly contain provisions for payments to governmental institutions or independent defined contribution pension plans of subsidiaries abroad.

An average cash outflow >5 years is expected. There is no discount, as the fair value of the pension liabilities is already discounted at the time the liability is calculated.

The <u>provisions for restructuring costs</u> concern the merger of sites in the USA ("Performance Polymers" business area) and the relocation of businesses in the "Fine Chemicals / Engineering" business area; the last one was concluded in 2009.

Within the <u>provisions for litigation risks</u>, the risk arising from litigation processes is adequately covered as at the time of preparation of the financial statements. CHF 3 million of the guarantee for warranties (see note 28) was used in 2009; the remaining CHF 16 million was reversed. A further CHF 22 million of the decrease is in connection with an adjusted estimate of a litigation risk, which is no longer regarded as probable. The reversal was made in the income statement via other operating income.

The increase of CHF 3 million is mainly due to a litigation risk regarded as probable.

Warranty provisions are mainly included within other provisions.

The non-current provisions for litigation risks and the non-current other provisions are expected with an average maturity of 2.5 years. The provisions are not discounted as the time value of money is not material. In relation to the total provisions the interest effect would be <3% as per December 31, 2009.

Notes		2009 (CHF '000)	2008 (CHF '000)
21	Other current liabilities		
	Advances from customers Prepaid expenses and deferred income Other current liabilities to related parties Other current liabilities to associated companies Liabilities to social security institutions Other current liabilities	2981 73892 0 3583 4473 27528	3645 46525 22 2428 6125 28408
	Total other current liabilities	112457	87 1 53
22	Liabilities, net / (net cash position) Bonds (see note 17) Option component of convertible bonds Pension liabilities (see note 20) Bank loans (see note 18) Other current liabilities to related parties (see note 21)	156 428 0 1 366 157 927 0	154209 10933 1447 166507 22
	Interest-bearing liabilities	315721	333118
	less Receivables from associated companies (see note 11) Securities Deposits (see note 13)	188 187 163 488 083	91 136098 446488
	Interest-bearing liabilities, net/(cash, net)	(359713)	(249 559)
	less Cash and cash equivalents (see note 13)	1021	1412
	Liabilities, net/(net cash position)	(360734)	(250971)

Consolidated Cash Flow Statement

EMS Group Consolidated Financial Statements Annual Report 2009/2010

Notes	5	2009 (CHF '000)	2008 (CHF '000)
23	Depreciation, amortisation and impairment of intangible assets and property, plant and equipment		
	Amortisation intangible assets Depreciation property, plant and equipment Impairment property, plant and equipment	4509 46312 6971	5939 45612 6647
	Total depreciation, amortisation and impairment of intangible assets and property, plant and equipment	57792	58 198
	For the breakdown of the depreciation, amortisation and impairment of intangible assets and property, plant and equipment please refer to note 8 and to the segment reporting.		
24	Purchase / disposal of fully consolidated companies		
	Cash outflow from purchase of fully consolidated companies and non-controlling interests		
	Acquisition of EMS-CHEMIE (Neumünster)		
	On November 16, 2009, EMS Group acquired EMS-CHEMIE (Neumünster) Holding GmbH, EMS-CHEMIE (Neumünster) GmbH & Co. KG and EMS-CHEMIE (Neumünster) Verwaltungs GmbH (former Nexis Group, Germany).		
	From November 16, 2009 to December 31, 2009, the acquired business contributed net sales revenue of CHF 4.2 million and a net loss of CHF 0.4 million to the EMS Group. If the acquisition had occurred on January 1, 2009, Group net sales revenue would have been CHF 36.7 million higher, while net income would have been CHF 1.3 million lower. These amounts have been calculated using the Group's accounting policies.		
	Net assets acquired and goodwill are shown as follows:		
	Purchase price in cash and cash equivalents Direct costs relating to the acquisition	3778 323	
	Total purchase price	4101	
	(Amount of assets acquired)	(4 107)	
	Goodwill / (negative goodwill)	(6)	

The acquisition of EMS-CHEMIE (Neumünster) has been accounted for using the purchase method. The following amounts of assets and liabilities acquired have been included in the consolidated financial statements:

(CHF '000)	Assets and liabilities included at acquisition date in consolidated financial statements	Adjustment through purchase price allocation	Assets and liabilities immediately before the combination
Intangible assets	5	0	5
Property, plant and equipment	3163	840	2 3 2 3
Other non-currents assets	456	216	240
Inventories	7980	1 080	6900
Trade accounts receivable	4918	(101)	5019
Other receivables	308	0	308
Cash and cash equivalents	2284	0	2 2 8 4
Non-current liabilities	(7988)	12917	(20905)
Trade accounts payable	(806)	0	(806)
Other current liabilities	(6213)	(641)	(5572)
Fair value of assets acquired	4107	14311	(10204)
Goodwill/(negative goodwill)	(6)		
Total cost of the business combination	4101		
Purchase price paid	4101		
Cash and cash equivalents of subsidiary acquired	(2284)		
Cash outflow from purchase of fully consolidated companies	1817		

Buyout of non-controlling interests at Changchun EFTEC Chemical Products Ltd.

On January 1, 2008, the participation of 60% was increased to 80%. The purchase price was KCHF 2642. At the same time it was agreed by contract that the participation will be increased to 100% on January 1, 2011. The purchase price was discounted to the value as per January 1, 2008, for the calculation of goodwill (see note 8). Total goodwill amounted to KCHF 3161.

Further Details

EMS Group Consolidated Financial Statements Annual Report 2009/2010

Notes		2009 (CHF '000)	2008 (CHF '000)
25	Contingent liabilities		
	Contingent liabilities at the end of the year amount to	12447	24 208
	This mainly relates to issued guarantees. No legal proceedings are known to be in progress within the EMS Group which could have a significant impact on the Group's financial position in excess of the provisions booked in the balance sheet (see note 20).		
26	Earnings per share – EPS		
	Earnings per share are calculated by dividing the net income attributable to the shareholders of EMS-CHEMIE HOLDING AG by the weighted average number of shares outstanding (excluding treasury shares). Diluted earnings per share factor in any potential dilution which may be caused by the exercising of warrant and conversion rights on outstanding bond issues.		
	Details of earnings per share:		
	Basic earnings per share		
	Weighted average of registered shares outstanding	22373911	22887970
	Net income, attributable to the shareholders of EMS-CHEMIE HOLDING AG	216138	211803
	Basic earnings per share (CHF)	9.66	9.25
	There is no earnings dilution; diluted earnings per share correspond to basic earnings per share.		
27	Significant shareholders		
	EMESTA HOLDING AG, Zug, 12091291 registered shares (2008: 12091291 registered shares) Amount of holding	51.70%	51.70%
	Miriam Blocher, 2079000 registered shares (2008: 2079000 registered shares) Amount of holding	8.89%	8.89%
	No other representation of significant shareholders is known to the Board of Directors.	/ 0	

es		2009 (CHF '000)	200 (CHF '000
	Transactions with related parties		
	EMESTA HOLDING AG, Zug (majority shareholder), the pension funds, members of the Board of Directors and members of the Senior Management as well as the close members of their families and associated companies are regarded as related parties. For financial key figures of the significant associated company, see note 32.		
	The members of the Board of Directors or Senior Management as well as the close members of their families did not receive any credits, advances or other types of loans. No related party transactions took place with them.		
	The bonuses included in the reporting year consist of the bonuses estimated in the reporting year. The definitive bonuses for the reporting year are announced after the publication of this financial report and are presented in the annual report 2009/2010 in the financial statements of EMS-CHEMIE HOLDING AG.		
	Breakdown of the total compensation		
	Short-term employee benefits to the members of the Board of Directors	0711	0.01
	and Senior Management Share-based payment	2711 0	291
	Termination benefits	Ő	
	Post-employment benefits	0	
	Other long-term employee benefits	0	0.01
	Total compensation	2711	291
	The detailed disclosures of compensation as per Swiss law can be found in the financial statements of EMS-CHEMIE HOLDING AG.		
	Existing shareholdings, conversion rights and options in EMS-CHEMIE HOLDING AG of the members of the Board of Directors and members of the Senior Management as well as their related parties are as follows:		
	Board of Directors	Number	of shares
	Dr. U. Berg, Chairman	2350	1.50

Dr U. Berg, Chairman	2350	1 500
M. Martullo, Vice-Chairman and CEO *	558 805	558 805
Dr H.J. Frei, Member	1720	1720
Dr W. Prätorius, Member	0	0
E. Appel, Member (until August 8, 2009)	-	1 200
Total Board of Directors	562875	563 225

* Excluding EMESTA HOLDING AG, in which M. Martullo holds a 49.9% stake (see note 27).

es	2009	2008
Senior Management	Number	of shares
M. Martullo, Vice-Chairman and CEO * sł P. Germann, CFO Dr R. Holderegger, Member (from October 9, 2009) R. Fintschin, Member (until October 8, 2009)	nown under "Boarc 0 0 –	l of Directors" 0 – 750
Total Senior Management	0	750
* Excluding EMESTA HOLDING AG, in which M. Martullo holds a 49.9% stake (see note 27).		
Neither the members of the Board of Directors and the Senior Management nor their related parties have any conversion rights or options in EMS-CHEMIE HOLDING AG.		
In connection with the sale of Atisholz to EMESTA HOLDING AG in 200 EMS-CHEMIE HOLDING AG issued a guarantee for warranties. This guarantee was CHF 19 million at December 31, 2008. CHF 3 million were used in 2009 (2008: –) (see note 20). The remaining CHF 16 millio were reversed in 2009 as there was no further obligation against EMESTA HOLDING AG as per December 31, 2009.		
Subsequent events		
On January 21, 2010, it was announced that the automotive aftermarked business "EFTEC Aftermarket" was sold. On February 15, 2010, it was announced that EMS-CHEMIE HOLDING AG sold 1015117 treasury shares, corresponding to a shareholding of 4.34% in EMS, to the main shareholder EMESTA HOLDING AG. The consolidated financial statements were approved by the Board of Directors on March 31, 2010 and need to be approved by the Annual General Meeting on August 14, 2010. Between December 31, 2009 and March 31, 2010 there were no further subsequent events requiring an adjustment of the book values of Group assets and liabilities or needing to be published here.	er	

Name	Domicile	Country
EMS-CHEMIE HOLDING AG	Domat/Ems	Switzerland
EMS-INTERNATIONAL FINANCE (Guernsey) Ltd.	Guernsey	Guernsey
EMS-FINANCE (Guernsey) Ltd.	Guernsey	Guernsey
EMS-MANAGEMENT SERVICES (Guernsey) Ltc	I. Guernsey	Guernsey
EMS-PATENT AG	Domat/Ems	Switzerland
BUSINESS AREA PERFORMANCE POLYMERS		
EMS-CHEMIE AG	Domat/Ems	Switzerland
EMS-CHEMIE (France) S.A.	Boulogne	France
EMS-CHEMIE (UK) Ltd.	Stafford	UK
EMS-CHEMIE (Japan) Ltd.	Tokyo	Japan
EMS-UBE Ltd.	Ube	Japan
EMS-CHEMIE (Italia) S.r.l.	Milano	Italy
EMS-CHEMIE (Deutschland) GmbH	Gross-Umstadt	Germany
EMS-CHEMIE (Taiwan) Ltd.	Hsin Chu Hsien	Taiwan (R. O. C.)
EMS-CHEMIE (China) Ltd.	Shanghai	China (People's Rep.)
EMS-CHEMIE (Suzhou) Ltd.	Suzhou	China (People's Rep.)
EMS-GRILON HOLDING Inc.	Wilmington, DE	USA
EMS-CHEMIE (North America) Inc.	Sumter, SC	USA
EFTEC Europe Holding AG	Zug	Switzerland
EFTEC AG	Romanshorn	Switzerland
EFTEC Sàrl	Montataire Cedex	France
EFTEC Engineering GmbH	Markdorf	Germany
EFTEC Ltd.	Rhigos	UK
EFTEC NV	Genk	Belgium
EFTEC S.A.	Zaragoza	Spain
EFTEC Asia Pte. Ltd.	Singapore	Singapore
EFTEC (Thailand) Co. Ltd.	Rayong	Thailand
EFTEC Shroff (India) Ltd.	Mumbai	India
EFTEC (China) Ltd.	Hong Kong	China (People's Rep.)
Shanghai EFTEC Chemical Products Ltd.	Shanghai	China (People's Rep.)
Changchun EFTEC Chemical Products Ltd.	0	China (People's Rep.)
Wuhu EFTEC Chemical Products Ltd.	Wuhu	China (People's Rep.)
D PLAST – EFTEC a.s.	Zlín	Czech Republic
EMS-TOGO Corp.	Taylor, MI	USA
EFTEC North America, L.L.C.	Troy, MI	USA
EFTEC Latin America S.A.	Panama City	Panama
EFTEC Brasil Ltda.	Sorocaba	Brazil
EFTEC Aftermarket GmbH	Lügde	Germany
BUSINESS AREA FINE CHEMICALS / ENGINEERING	3	
EMS-GRILTECH *		
EMS-PATVAG AG in Liquidation	Domat/Ems	Switzerland
EMS-PATVAG s.r.o.	Brankovice	Czech Republic
EMS-METERING AG	Domat/Ems	Switzerland
EMS-CHEMIE (Neumünster) Holding GmbH	Neumünster	Germany
EMS-CHEMIE (Neumünster) GmbH & Co. KG	Neumünster	Germany
EMS-CHEMIE (Neumünster) Verwaltungs Gmbl	H Neumünster	Germany

Currency	Share capital (in '000)	Holding Group	direct	Category	Consolidation
CHF	234			D	К
CHF	60	100.00%	100.00%	D	К
CHF	1	100.00%	100.00%	D	K
CHF]	100.00%	100.00%	D	K
CHF	100	100.00%	100.00%	D	К
CHF	100	100.00%	100.00%	P,V	К
EUR	1951	100.00%	100.00%	V	K
GBP	1 530	100.00%	100.00%	\vee	К
JPY	210000	100.00%	100.00%	\vee	Κ
JPY	1 500 000	66.67%	66.67%	P,V	K
EUR	1 300	100.00%	100.00%	V	К
EUR	2556	100.00%	100.00%	P,V	К
TWD	281 000	100.00%	100.00%	P,V	K
CNY	5 000	100.00%	100.00%	V	K
CNY	98693	100.00%	100.00%	Р	К
USD	2420	100.00%	95.87%	D	К
USD	11285	100.00%	100.00%	P,V	K
CHF	8 000	100.00%	70.00%	D	К
CHF	2500	100.00%	100.00%	P,V	К
EUR	8	100.00%	100.00%	V	K
EUR	25	100.00%	100.00%	P,V	K
GBP	352	100.00%	100.00%	P,V	K
EUR	1 240	100.00%	100.00%		K
				P,V	
EUR	944	100.00%	100.00%	P,V	K
USD	3518	80.00%	80.00%	D,V	K
ТНВ	49500	80.00%	100.00%	P,V	K
INR	15000	39.20%	49.00%	P,V	E
USD	3700	80.00%	100.00%	D	К
CNY	20750	48.00%	60.00%	P,V	K
CNY	27 500	80.00%	100.00%	P,V	K
CNY	6650	48.00%	60.00%	P,V	K
CZK	47 569	50.00%	50.00%	P,V	E
USD	750	100.00%	100.00%	D	K
USD	38 222	100.00%	100.00%	P,V	К
USD	0	100.00%	88.50%	D	К
BRL	541	100.00%	100.00%	Р	К
EUR	1 023	100.00%	100.00%	P,V	К
	100	100.000/	100.000/		
CHF	100	100.00%	100.00%	P,V	K
CZK	30 000	100.00%	100.00%	P,V	К
CHF	100	100.00%	100.00%	D	K
EUR	25	100.00%	100.00%	D	К
EUR	3 000	100.00%	100.00%	P,V	К
EUR	25	100.00%	100.00%	D	K
				-	.、

	Notes	2009 (CHF '000)	2008 (CHF '000)
--	-------	--------------------	--------------------

31 Change in scope of consolidation

Fully consolidated:

Addition:

EMS-CHEMIE (Neumünster) Holding GmbH, EMS-CHEMIE (Neumünster) GmbH & Co. KG and EMS-CHEMIE (Neumünster) Verwaltungs GmbH: These companies were acquired on November 16, 2009 (see note 24).

32 Significant associated company

D PLAST – EFTEC a.s.		
Domicile	Zlín, Czech	n Republic
Percentage held		50.00%
Financial year	January 1, 2009–December	31,2009
Category	Produc	tion, Sale
Currency		CZK
Net sales revenue	KCHF	39085
Net income	KCHF	7925
Assets	KCHF	36579
Equity	KCHF	25933
Liabilities	KCHF	10646

33 Risk management

Credit risks		
Overview of financial assets		
Other non-current financial assets (see note 8) Trade accounts receivable (see note 10) Receivables from associated companies (see note 11) Derivative financial instruments (see note 12) Cash and cash equivalents (see note 13)	1 091 203 569 188 8 493 489 104	763 170742 91 40972 447900
Total financial assets	702445	660468
The maximum credit risk is equal to the carrying amount of the respective assets. There are no collateralised financial assets. For the analysis of due dates and allowances for doubtful accounts on trade accounts receivable, see note 10.		

Notes

The maturity date of financial liabilities is	as follows:				
At 31.12.2009 (CHF '000)	Carrying amount	Contractual Cash flows	<1 year	Maturity date 1 – 5 years	>5 years
Non-derivative financial liabilities:					
Bonds (see note 17)	156428	161089	161089	0	0
Current bank loans (see note 18)	7927	7927	7927	0	0
Non-current bank loans (see note 18)	150000	156750	2850	153900	0
Trade accounts payable	98638	98638	98638	0	0
Other current liabilities to associated companies (see note 21)	3 583	3 583	3 583	0	0
Derivative financial liabilities:					
Option component of convertible bonds	0	0	0	0	0
Derivative financial instruments (see note 12)	149	149	104	45	0
Total financial liabilities	416725	428136	274191	153945	0

At 31.12.2008 (CHF '000)	Carrying amount	Contractual Cash flows	<1 year	Maturity date 1 – 5 years	>5 years
Non-derivative financial liabilities:					
Bonds (see note 17)	154209	165018	3929	161089	0
Current bank loans (see note 18)	16507	16507	16507	0	0
Non-current bank loans (see note 18)	150000	159600	2850	156750	0
Trade accounts payable	70842	70842	70842	0	0
Other current liabilities to related parties (see note 21)	22	22	22	0	0
Other current liabilities to associated companies (see note 21)	2 4 2 8	2 4 2 8	2 4 2 8	0	0
Derivative financial liabilities:					
Option component of convertible bonds	10933	0	0	0	0
Derivative financial instruments (see note 12)	3059	3059	3059	0	0
Total financial liabilities	408 000	417476	99637	317839	0

Market risks

Interest rate risks

Sensitivity analysis of interest rate risks

The bonds and the non-current bank loans have a fixed interest rate. The valuation of the bonds is at amortised costs. There are no derivative financial instruments on interest rates used. An increase/ (decrease) in the interest rate of 100 basis points in the case of the deposits and the current bank loans would increase / (decrease) net income after taxes by CHF 4.0 million (2008: CHF 3.1 million). This sensitivity analysis assumes that all other assumptions, e.g. currency rates, remain unchanged. The sensitivity analysis was performed on the same basis as for the previous year.

Currency risks						
Overview currency exposure, net						
At 31.12.2009 (CHF '000)	CHF	EUR	USD	JPY	TWD	Other currencies
Trade accounts receivable (see note 10)	37 446	77 447	15143	23025	18106	32 402
Loans to group companies	40837	36 479	96517	2800	0	3 3 2 0
Derivative financial instruments (see note 12)	0	0	0	89628	0	12710
Trade accounts payable	(44064)	(20757)	(8031)	(15992)	(1501)	(8293)
Current bank loans (see note 18)	Ó	Ó	Ó	(6720)	Ó	(1 207)
Derivative financial instruments (see note 12)	0	(119538)	(1193)	Ó	0	Ó
Currency exposure, net	34219	(26369)	102 436	92 741	16605	38932
Af 31.12.2008 (CHF '000)	CHF	EUR	USD	JPY	TWD	Other
Trade accounts receivable (see note 10)	33074	56 499	17069	28941	10897	24 262
Loans to group companies	31 679	43 000	79 592	4 680	0	4 3 5 5
Derivative financial instruments (see note 12)	0	0	0	177709	0	4680
Trade accounts payable	(24093)	(11883)	(8216)	(20501)	(2309)	(3840)
Loans from group companies	ν ΄ ΄	(2906)	(693)	ν ΄	Û Û	(687)
Current bank loans (see note 18)	0	Ó) Ó	(15269)	0	(1238)
Derivative financial instruments (see note 12)	0	(365930)	(128623)	0	0	(7583)

Sensitivity analysis of currency risks

A 10% increase / (decrease) in the Swiss franc (CHF) against all other currencies would decrease / (increase) net income after taxes by CHF 10.0 million (2008: CHF 7.9 million). Per currency: EUR: CHF – 2.7 million (2008: CHF – 3.7 million), USD: CHF – 2.5 million (2008: CHF – 1.0 million), JPY: CHF – 0.1 million (2008: CHF – 0.3 million), other currencies: CHF – 4.7 million (2008: CHF – 2.9 million). A 10% increase / (decrease) in the Swiss franc (CHF) against all other currencies would decrease / (increase) equity after taxes by CHF 7.7 million (2008: CHF 11.9 million increase / [decrease]). Per currency: EUR: CHF + 7.9 million (2008: CHF + 22.3 million), USD: CHF – 8.5 million (2008: CHF + 0.7 million), JPY: CHF – 2.4 million (2008: CHF – 8.2 million), other currencies: CHF – 4.7 million (2008: CHF – 2.9 million).

This sensitivity analysis was performed at the balance sheet date and assumes that all other assumptions, e.g. interest rates, remain unchanged. The sensitivity analysis was performed on the same basis as for the previous year.

2009	200
86% 14% 0%	99% 0% 1%
100%	100%
	0%

Sensitivity analysis of securities risks

A 10% increase in the fair value of available-for-sale securities and option component of convertible bonds would increase equity after taxes by CHF 18.0 million (2008: CHF 13.6 million), while the net income after taxes would be CHF 0.0 million (2008: CHF 19.4 million) lower. A 10% decrease in the fair value of available-for-sale securities and option component of convertible

bonds would decrease equity after taxes by CHF 18.0 million (2008: CHF 13.6 million), while net income after taxes would be CHF 0.0 million (2008: CHF 19.1 million) higher.

The sensitivity analysis was performed on the same basis as for the previous year.

Financial assets / liabilities: fair value hierarchy

At 31.12.2009 (CHF '000)	Level 1	Level 2	Level 3	Total
Financial assets: Available-for-sale securities Derivative financial instruments (see note 12)	187163	8493		187163 8493
Financial liabilities: Option component of convertible bonds Derivative financial instruments (see note 12)		0 (149)		0 (149)

There were no transfers between the levels of the fair value hierarchy.

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs for the asset or liability that are not based on observable market data.

34 Information about the risk assessment process

Risk management constitutes an integral component of planning and reporting activities at EMS. At Senior Management and Business Unit level, risks are identified annually as part of the medium-term planning procedure and preparation of the budget for the following year. They are then weighted according to the gravity of the risk and probability of its occurrence. The identification and assessment of changes in risk play an important part in this process. Measures are defined to reduce significant risks. In the course of planning discussions, the CEO and CFO report to the Board of Directors on the magnitude of these risks and the implementation status of the measures taken to counter them.



Report of the Statutory Auditor on the Consolidated Financial Statements to the Annual General Meeting of EMS-CHEMIE HOLDING AG, Domat / Ems

As Statutory Auditor, we have audited the consolidated financial statements of EMS-CHEMIE HOLDING AG, which comprise the income statement, statement of comprehensive income, balance sheet, statement of changes in equity, statement of cash flows and notes (pages 19 to 57) for the year ended December 31, 2009.

Board of Directors' Responsibility

The Board of Directors is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and the requirements of Swiss law. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards as well as International Standards on Auditing. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements for the year ended December 31, 2009 give a true and fair view of the financial position, the results of operations and the cash flows in accordance with International Financial Reporting Standards (IFRS) and comply with Swiss law.

Report on Other Legal Requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO and article 11 AOA) and that there are no circumstances incompatible with our independence.

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of consolidated financial statements according to the instructions of the Board of Directors.

We recommend that the consolidated financial statements submitted to you be approved.

Zurich, March 31, 2010

KPMG AG

A. Houl

Hanspeter Stocker Licensed audit expert Auditor in charge

Georg Mosimann Licensed audit expert

Financial Statements EMS-CHEMIE HOLDING AG

for the Financial Year May 1, 2009 – April 30, 2010



Income Statement May 1, 2009 to April 30, 2010

EMS-CHEMIE HOLDING AG Financial Statements Annual Report 2009/2010

Notes	2009 / 2010 (CHF '000)	2008/2009 (CHF '000)
INCOME		
License fees from group companies	33 854	35 449
Financial income		
Interest income	4 388	6153
Foreign exchange differences 1	354	8 870
Dividends on group companies	123 900	156410
Income from financial assets	58 974	31 022
Other income	0	164
Total income	221 470	238 068
Financial expenses		
EXPENSES Operating expenses to group companies	20 295	20 672
Expenses from financial assets	2 776	38 2 34
Interest expenses	7 7 6 4	11 064
Expenses from disposal of group companies	772	
		0
Bank charges, duties, fees	302	0 1 045
Bank charges, duties, fees	302 1 520	
		1 045 1 520
Bank charges, duties, fees Administration expenses	1 520	1 045 1 520 0
Bank charges, duties, fees Administration expenses Expenses arising from guarantees 2	1 520 2 762	1 045

164 423

184 800

...

Net income

Balance Sheet as at April 30, 2010

EMS-CHEMIE HOLDING AG Financial Statements Annual Report 2009/2010

	Notes	30.4.2010 (CHF '000)	30.4.2009 (CHF '000)
Non-current assets		350 698	374 436
Investments in group companies	3	284 991	291 107
Loans to group companies		65 707	83 329
Current assets		325 395	288 623
Prepayments and accrued income		13 328	10398
Accounts receivable from third parties		698	631
Accounts receivable from group companies		42 784	42 461
Loans to group companies		3 6 6 4	0
Current financial assets	4	84 777	90832
Cash and cash equivalents		180144	144 301
TOTAL ASSETS		676 093	663 059

Shareholders' equity	5	466967	394 037
Share capital	677	234	234
Legal reserves		47	47
Reserves for treasury shares	4	0	130 403
Other reserves		10 000	10 000
Available earnings		456 686	253 353
Liabilities		209126	269 022
Non-current liabilities		64 169	164169
Bank loans		50 000	150 000
Provisions		14169	14169
Current liabilities		144 957	104 853
Loans from group companies		0	79 630
Bank loans		100 000	0
Accruals and deferred income		8 0 5 9	8010
Accounts payable to third parties		6 060	1 997
Accounts payable to group companies		30 838	15216
TOTAL EQUITY AND LIABILITIES		676 093	663 059
Balance sheet equity ratio		69.1%	59.4%

EMS-CHEMIE HOLDING AG Financial Statements Annual Report 2009/2010

Income Statement 2009/2010

Note	S	2009/2010 (CHF '000)	2008 / 2009 (CHF '000)
1	Foreign exchange differences Foreign exchange gains Foreign exchange losses	8 101 7 747	24652 15782
	Foreign exchange differences	354	8 870
2	Expenses arising from guarantees In connection with the sale of Atisholz to EMESTA HOLDING AG in 2001, EMS-CHEMIE HOLDING AG issued a guarantee for warranties. This guarantee was CHF 19 million as at 30.04.09. In 2009/2010, CHF 3 million was used (2008/2009: –). There was no further obligation against EMESTA HOLDING AG as at 30.04.10.		
Ba	lance Sheet as at April 30, 2010		
3	Investments in group companies Details of the investments as at 31.12.09 can be seen in note 30, "List of subsidiaries and non-controlling interests", in the consolidated		

Notes		2009/2010 (CHF '000)	2008 / 2009 (CHF '000)
4	Current financial assets		
	Securities	84777	2517
	Treasury shares	0	88315
	Current financial assets	84777	90832
	Details to treasury shares: Nu At 01.05.	mber of regist 1015117	2580393
	Purchases	0	129710
	Disposals	(1015117)	(4 0 5 6)
	Conversion	0	(27088)
	Redemption of share capital	0	(1663842)
	At 30.04.	0	1015117
	1015117 treasury shares were sold on stock exchange at a market price of CHF 127.10 to the main shareholder EMESTA HOLDING AG. The dividend adjusted acquisition price was CHF 97.55.		
	Previous year: Purchase of 129710 treasury shares at an average market price of CHF 133.21, sale of 4056 treasury shares at an average market price of CHF 132.80. Of the 2% convertible bond 2002–25.07.08, in 2008/2009 convertible bonds with a nominal value of KCHF 3440 were converted into 27088 treasury shares (see note 8). From the repurchase of registered shares by virtue of put options, 1 663842 registered shares were canceled on 03.11.08.		
5	Shareholders' equity		
	At 01.05.	394037	691336
	Dividends paid	(111870)	(162231)
	Redemption of share capital Net income	0 184800	(299491) 164423
	At 30.04.	466 967	394 037

	2009/2010	2008 / 2009
Notes	(CHF '000)	(CHF '000)

6 Share capital

	Par value	Number of issued registered shares	Number of treasury shares	Number of shares entitled to dividend	Share capital (CHF '000)
At 30.04.08	CHF 0.01	25052870	2580393	22472477	251
Change in treasury shares Redemption of share capital		- (1 663 842)	98 566 (1 663 842)	(98 566) –	(17)
At 30.04.09	CHF 0.01	23389028	1015117	22373911	234
Sale of treasury shares		-	(1015117)	1015117	_
At 30.04.10	CHF 0.01	23389028	0	23389028	234

7	Significant shareholders EMESTA HOLDING AG, Zug, 13106408 registered shares (2008/2009: 12091291 registered shares) Amount of holding Miriam Blocher, 2079000 registered shares (2008/2009: 2079000 registered shares) Amount of holding No other representation of significant shareholders is known to the Board of Directors.	56.04% 8.89%	51.70% 8.89%
8	Bonds In 2008 / 2009, convertible bonds with a nominal value of KCHF 3 440 were converted into treasury shares (see note 4) and convertible bonds with a nominal value of KCHF 76 460 into Lonza shares. At 25.07.08, the 2% convertible bond 2002 – 25.07.08, and at 29.07.08, the 4 % debenture bond 2002 – 29.07.08, were repaid.		

Further Details

S		2009 / 2010 (CHF '000)	2008 / 2009 (CHF '000
Contingent liabilit Guarantees (maxi		164020	569942
To secure the con by EMS-INTERNA EMS-CHEMIE HC	vertible bond in the amount of CHF 350 million issued NTIONAL FINANCE (Guernsey) Ltd. in April 2002, DLDING AG granted a guarantee in the amount of . At 23.04.10, the convertible bond was repaid and		
Compensation ar The following com	d shareholdings pensation was paid in the reporting year:		
Board of Directors	s Function	Compe	nsation
Dr U. Berg M. Martullo Dr H.J. Frei Dr W. Prätorius E. Appel A. Reich	Chairman Vice-Chairman and CEO Member * Member Member (until 08.08.09) Member (until 09.08.08)	191 936 330 105 105	19 71: 25, 10: 10: 19:
Total Board of Dir	ectors	1 667	1 56
the Foundation E as Member of th Senior Managem Total compensatio	on paid to the Senior Management was	2200	184
in the reporting ye	ensation for a member of the Senior Management ear was KCHF 936 (2008 / 2009: KCHF 715) and was Ilo, Vice-Chairman of the Board of Directors and CEO.		
and Senior Mar	n is paid exclusively in cash.	2931	269.
Advisory board There is no advisc	bry board.		
or Senior Manage members of the Be was paid on an c	was paid to former members of the Board of Directors ement. Furthermore, all compensation for current or former bard of Directors, Senior Management and related parties irm's length basis. The current as well as former members rectors, Senior Management and related parties did not or credits.		

S		2009 / 2010	2008 / 2009
HOLDING AG held by	conversion rights and options in EMS-CHEMIE members of the Board of Directors, members nent and related parties were as follows:		
Board of Directors	Function	Number of regi	stered share
Dr U. Berg M. Martullo Dr H.J. Frei Dr W. Prätorius E. Appel	Chairman Vice-Chairman and CEO * Member Member Member (until 08.08.09)	2350 558805 2330 1000 -	1 50 558 80 1 72 1 20
Total Board of Director	S	564 485	563 22
Senior Management	Function		
M. Martullo P. Germann Dr R. Holderegger R. Fintschin	CEO * sh CFO Member (from 09.10.09) Member (until 08.10.09)	nown under "Boarc 0 0 –	l of Director 75
Total Senior Managem	ent	0	75
49.9% stake (see not The members of the Bo	ard of Directors, Senior Management and hold any conversion rights or options in		
reporting activities at E Unit level, risks are iden planning procedure ar year. They are then we probability of its occurr changes in risk play ar defined to reduce sign the CEO and CFO rep	risk assessment process titutes an integral component of planning and MS. At Senior Management and Business ntified annually as part of the medium-term ad preparation of the budget for the following ighted according to the gravity of the risk and rence. The identification and assessment of important part in this process. Measures are ficant risks. In the course of planning discussions, ort to to the Board of Directors on the magnitude nplementation status of the measures taken		

Proposal of the Board of Directors for the appropriation of available earnings

EMS-CHEMIE HOLDING AG Financial Statements Annual Report 2009/2010

	2009 / 2010 (CHF)	2008 / 2009 (CHF)
Available earnings		
Net income	184799928	164 423 101
Reclassification reserves for treasury shares	130403016	(13314414)
Balance brought forward	141483153	102244021
Total available earnings	456686097	253 352 708
Appropriation		
Payment of an ordinary dividend of CHF 5.00 (previous year CHF 5.00) gross and a special dividend of CHF 5.00	(116945140)	(111869555)
(previous year CHF 0.00) gross per registered share entitled to dividend	(116945140)	0
Balance to be carried forward	222795817	141 483 153



Report of the Statutory Auditor on the Financial Statements to the Annual General Meeting of EMS-CHEMIE HOLDING AG, Domat / Ems

As statutory auditor, we have audited the financial statements of EMS-CHEMIE HOLDING AG, which comprise the income statement, balance sheet and notes (pages 60 to 67) for the year ended April 30, 2010.

Board of Directors' Responsibility

The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the company's articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements for the year ended April 30, 2010 comply with Swiss law and the company's articles of incorporation.

Report on Other Legal Requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO and article 11 AOA) and that there are no circumstances incompatible with our independence.

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We further confirm that the proposed appropriation of available earnings complies with Swiss law and the company's articles of incorporation. We recommend that the financial statements submitted to you be approved.

Zurich, May 26, 2010

KPMG AG

A. Nod

Hanspeter Stocker Licensed audit expert Auditor in charge

Georg Mosimann Licensed audit expert

Addresses of EMS Companies, Switzerland

EMS-CHEMIE HOLDING AG

Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 61 11 Fax +41 81 632 74 01 www.ems-group.com info@ems-group.com

EMS-CHEMIE HOLDING AG

Fuederholzstrasse 34 CH-8704 Herrliberg Phone +41 44 915 70 00 Fax +41 44 915 70 02 www.ems-group.com info@ems-group.com

EMS-CHEMIE AG

Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 61 11 Fax +41 81 632 74 01 www.ems-group.com welcome@emschem.com

EMS-CHEMIE AG

Fuederholzstrasse 34 CH-8704 Herrliberg Phone +41 44 915 70 00 Fax +41 44 915 70 02 www.ems-group.com info@ems-group.com

EMS-CHEMIE AG

Kugelgasse 22 CH-8708 Männedorf Phone +41 44 921 00 00 Fax +41 44 921 00 01 www.ems-group.com info@ems-group.com

EMS-CHEMIE AG

Business Unit EMS-GRIVORY Europe Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 78 88 Fax +41 81 632 76 65 www.emsgrivory.com welcome@emsgrivory.com

EMS-CHEMIE AG

Business Unit EMS-GRILTECH Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 72 02 Fax +41 81 632 74 02 www.emsgriltech.com info@emsgriltech.com

EMS-CHEMIE AG

Business Unit EMS-SERVICES Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 77 66 Fax +41 81 632 76 76 www.emsservices.ch welcome@emsservices.ch

EMS-PATENT AG

Via Innovativa 1 CH-7013 Domat/Ems Phone +41 81 632 68 26 Fax +41 81 632 74 40 info@emspatent.com

EFTEC AG

Hofstrasse 31 CH-8590 Romanshorn Phone +41 71 466 43 00 Fax +41 71 466 43 01 www.eftec.ch info@eftec.ch

Belgium

EFTEC NV Henry Fordlaan 1 B-3600 Genk Phone +32 89 65 14 00 Fax +32 89 65 14 80

Brazil

EFTEC Brasil Ltda. Av. Charles Goodyear, 521 Cururuquara CEP 06524-115 Santana de Parnaiba, SP Brazil Phone +55 11 4193 1353 Fax +55 11 4193 1148

China

EMS-CHEMIE (China) Ltd. 227 Songbei Road Suzhou Industrial Park Suzhou City 215126 Jiangsu Province P.R. China Phone +86 512 8666 8180 Fax +86 512 8666 8210 welcome@cn.emsgrivory.com

EMS-CHEMIE (Suzhou) Ltd.

227 Songbei Road Suzhou Industrial Park Suzhou City 215126 Jiangsu Province P.R. China Phone +86 512 8666 8181 Fax +86 512 8666 8183 welcome@cn.emsgrivory.com

Shanghai EFTEC

Chemical Products Ltd. Humin Road 521 Guanghua Road Shanghai 201108 P.R. China Phone +86 21 6489 1122 Fax +86 21 6489 1199 EFTEC Asia Pte. Ltd. Shanghai Representative Office Unit 1008 Super Ocean Finance Center 2067 Yan An Road West Shanghai 200336 P.R. China Phone +86 21 6295 7716 Fax +86 21 6295 7816

Changchun EFTEC Chemical Products Ltd. No. 808 Chuangxin Road Changchun 130012 P.R. China Phone +86 431 8508 0800 Fax +86 431 8508 0808

Wuhu EFTEC

Chemical Products Ltd. No. 215 Yinhu North Road Wuhu 241009 Anhui Province P.R. China Phone +86 553 596 5155 Fax +86 553 596 5155

EFTEC China Ltd. 3313-3317, Jardine House 1 Connaught Place, Central Hong Kong Phone +852 2526 4868 Fax +852 2526 6568

Czech Republic

D PLAST-EFTEC a.s. U Tescomy 206 CZ-760 01 Zlín Phone +420 577 004 411 Fax +420 577 004 444 zlin@dplast-eftec.cz

D PLAST-EFTEC a.s. Větrná 445 CZ-463 34 Hrádek nad Nisou Phone +420 482 429 511 Fax +420 482 429 504 hradek@dplast-eftec.cz

EMS-PATVAG s.r.o. Brankovice č.p. 350 CZ-683 33 Brankovice Phone +420 517 302 200 Fax +420 517 302 222 welcome@emspatvag.cz

France

EMS-CHEMIE (France) S.A. 73–77, rue de Sèvres Boîte postale 52 F-92105 Boulogne-Billancourt Cedex Phone +33 1 41 10 06 10 Fax +33 1 48 25 56 07 welcome@fr.emsgrivory.com

EFTEC Sàrl

Les Marches de l'Oise Bâtiment Copenhague 100, rue Louis Blanc F-60765 Montataire Cedex Phone +33 3 44 24 19 18 Fax +33 3 44 24 97 10

Germany

EMS-CHEMIE (Deutschland) GmbH Warthweg 14 D-64823 Gross-Umstadt Phone +49 6078 783 0 Fax +49 6078 783 158 welcome@de.emsgrivory.com

EMS-CHEMIE (Neumünster) GmbH & Co. KG Tungendorfer Str. 10 D-24536 Neumünster Phone +49 4321 302 500 Fax +49 4321 302 511 info.nms@de.emsgriltech.com

EFTEC Engineering GmbH Dornierstrasse 7 D-88677 Markdorf Phone +49 7544 920 0 Fax +49 7544 920 200

Great Britain

EMS-CHEMIE (UK) Ltd. Darfin House, Priestly Court Staffordshire Technology Park GB-Stafford ST18 0AR Phone +44 1785 283 739 Fax +44 1785 283 722 welcome@uk.emsgrivory.com

EFTEC Ltd.

Rhigos/Aberdare GB-Mid Glamorgan CF44 9UE Phone +44 1685 81 54 00 Fax +44 1685 81 39 97

Guernsey

EMS-INTERNATIONAL FINANCE (Guernsey) Ltd. Trafalgar Court 3rd Floor, West Wing St. Peter Port Guernsey GY1 2JA Channel Islands Phone +44 1481 712 704 Fax +44 1481 712 705

India

EFTEC Shroff (India) Ltd. Oberoi Chambers II, 4th floor New Link Road Andheri (West) Mumbai 400 053 India Phone +91 22 2674 7900 Fax +91 22 2673 6013 esil@eftecindia.com

Italy

EMS-CHEMIE (Italia) S.r.I. Via Visconti di Modrone, 2 I-20122 Milano Italia Phone 00 800 1100 1122 * Fax 00 800 1100 2233 * welcome@it.emsgrivory.com * from Italy only

Japan

EMS-CHEMIE (Japan) Ltd. EMS Building 2-11-20 Higashi-koujiya Ota-ku, Tokyo 144-0033 Japan Phone +81 3 5735 0611 Fax +81 3 5735 0614 www.emsgrivory.co.jp welcome@jp.emsgrivory.com

EMS-CHEMIE (Japan) Ltd.

Osaka Office, Umeda Shinmichi Bldg. 1-1-5, Dojima, Kita-ku Osaka 530-0003 Japan Phone +81 6 6348 1655 Fax +81 6 6348 1702 info@jp.emsgriltech.com

EMS-UBE Ltd.

1978-10 Kogushi Ube-shi, Yamaguchi 755-8633 Japan Phone +81 836 31 02 13 Fax +81 836 31 02 14

Mexico

Grupo Placosa EFTEC S.A. de C.V. Calle 56 sur No. 11 Civac Jiutepec Mor. C.P. 62500 Cuernavaca Mor. Mexico Phone +52 777 319 3477 Fax +52 777 320 4240

Romania

S.C. AUTO COATING S.R.L. Budeasa Mare, Arges County 117 151 Budeasa Romania Phone +40 248 236 377

Fax +40 248 236 325 info@autocoating.eu

Russia

D PLAST-EFTEC NN

Pr. Iljicha 39-77 603 101 Nizhnij Novgorod Russia Phone +7 8312 996 889 Fax +7 8312 996 889 pavlov@defnn.ru

D PLAST-EFTEC RT

Ulica 20.1, Korpus 1/1 Promyslennaja Ploscadka Alabuga Elabuzhsky rayon 423 630 Elabuga Republic Tatarstan Russia Phone +7 85 557 519 40 Fax +7 85 557 519 41 r.gazizov@dplast-rt.ru

Singapore

EFTEC Asia Pte. Ltd. 15 Beach Road #03-07 Beach Centre Singapore 189677 Phone +65 6545 82 01 Fax +65 6337 28 06

Spain

EFTEC S.A.

Carretera Logroño km 29,2 E-50639 Figueruelas (Zaragoza) Phone +34 976 65 62 69 Fax +34 976 65 62 70

Taiwan

EMS-CHEMIE (Taiwan) Ltd. 36, Kwang Fu South Road Hsin Chu Industrial Park Fu Kou Hsiang Hsin Chu Hsien 30351 Taiwan, R.O.C. Phone +886 35 985 335 Fax +886 35 985 345 welcome@tw.emsgrivory.com info@tw.emsgriltech.com

Thailand

EFTEC (Thailand) Co. Ltd. 109/10 M 004, Pluakdaeng Rayong 21140 Thailand Phone +66 38 954 271 Fax +66 38 954 270

United States

EMS-CHEMIE

(North America) Inc. 2060 Corporate Way P.O. Box 1717 Sumter, SC 29151 USA Phone +1 803 481 91 73 Fax +1 803 481 38 20 welcome@us.emschem.com info@us.emsgriltech.com

EFTEC North America, L.L.C. 20219 Northline Road Taylor, MI 48180-4786 USA Phone +1 800 633 7789

Ukraine

JSC D PLAST-EFTEC UA UI. Gorkoho 27/29 69063 Zaporozhye Ukraine Phone +380 612 138 568 Fax +380 612 138 568 defua@email.com.ua



PERFORMANCE POLYMERS FINE CHEMICALS/ENGINEERING